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Abstract
Research in the field of neuroendocrine tumors (NETs) has increased over the last
decade, including studies focused on biochemical markers (biomarkers) of the disease.
There is also growing interest in how NETs impact patients’ quality of life (QOL).
Consequently, there is a paucity of information about whether the expression of the
specific disease biomarkers affects QOL as well as whether the primary tumor site
impacts QOL. Using the explanatory model of health promotion and quality of life in
chronic disabling conditions as the theoretical framework and data collected with the
Norfolk QOL-NET instrument, this study’s purpose was to fill that gap in knowledge
through research questions addressing the relationship between the primary tumor site
and NET patients’ total QOL score as well as the effect of specific NET biomarkers on
NET patients’ total QOL score. Data were analyzed using descriptive statistics, one-way
analysis of variance (ANOVA), regression analysis, and post hoc tests to determine
significance. Results from an ANOVA showed that abnormal NET biomarkers affected
total QOL (p = 0.011). In the analyses of whether the independent biomarker variables
affected the dependent total QOL variable, only the result for Serotonin Normal was
significant (p = 0.002). The presence of abnormal biomarker measurements also affected
two of the Norfolk QOL-NET domains significantly, gastrointestinal and physical
functioning (p = 0.005 and p = 0.030, respectively). By understanding the relationship
between NETs and patient QOL, the potential positive social change implications are
helping NET patients assess the severity of their condition, determining what affects their
well-being, and using this information to help monitor their treatment/progress.
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Chapter 1: Introduction to the Study
Introduction
Neuroendocrine tumors (NETs) have been referred to as a Cinderella condition
because of the lack of recognition for this group of heterogeneous tumors (Vinik, Silva,
& Vinik, 2011; Vinik, Vinik, Diebold, & Woltering, 2014). This lack of recognition
persists, despite over 100,000 patients living with NETs in the United States and an
increase in incidence over the last 30 years in the United States and Europe (Lawrence et
al., 2011; Öberg, Knigge, Kwekkeboom, & Perren, 2012; Tsikitis, Wertheim, &
Guerrero, 2012; Vinik, Carlton, Silva, & Vinik, 2009; Vinik et al., 2014). An increase in
the incidence of NETs is also evident in Asian countries such as Japan and Korea
(Hijioka et al., 2014; Lee et al., 2014). NETs develop in neuroendocrine cells throughout
the body—they often progress slowly and are usually diagnosed after the tumors have
metastasized (Haugland, Veenstra, Vatn, & Wahl, 2013; Mayo Clinic, 2013; Vinik et al.,
2014). There are no known methods for the early detection or prevention of NETs
(American Cancer Society [ACS], 2013; Ӧberg & Castellano, 2011; Tsikitis et al., 2012).
Research in the field of NETs has increased over the last decade, including an
interest in biomarkers that have a role in disease diagnosis, prognosis, monitoring, and
treatment (Ardill & Erikkson, 2003; Diebold et al., 2012; Modlin et al., 2008; Vinik et al.,
2014). Biomarkers can be used to help distinguish among tumor types or act as a generic
marker of NETs (Turaga & Kvols, 2011). There is increasing interest in how NETs
influence QOL as well—this interest has resulted in the development of two diseasespecific instruments. There is a body of research about the relationship between

2
biomarkers and NETs; however, there is very little information about whether the
expression of the disease’s novel biomarkers impacts patients’ QOL. There is also a lack
of information about whether a patient’s primary tumor site affects QOL. This study was
designed to fill those gaps. Results from this study could give physicians as well as
patients and caregivers a better understanding of how the disease affects an individual’s
QOL. In turn, that information can be used to develop treatment options and programs to
improve and maintain QOL for this patient population.
This chapter provides an overview of the research study. It includes background
information about NETs along with a description of the research problem and how it
addresses a gap in the research literature. The study’s purpose, research questions, and
hypothesis are also discussed. The theoretical framework, nature of the study,
assumptions, scope/delimitations, and limitations are provided as well. The chapter
concludes with an overview of the study’s significance. More detailed information about
existing research is discussed in Chapter 2.
Background
NETs were initially described in the mid- to late-19th century, and they continued
to be defined through the present day (Hauso et al., 2007; Modlin et al., 2008; Ӧberg &
Castellano, 2011; Turaga & Kvols, 2011; Van Eeden et al., 2002). Located throughout
the body, neuroendocrine cells are similar to nerve cells and endocrine cells (ACS, 2013).
This wide dispersion of cells contributes to the heterogeneity of NETs and the possibility
of different primary tumor sites (e.g., appendix, colon, ileum, intestines, lungs, pancreas,
or rectum; ACS, 2013; Mayo Clinic, 2013). The most common types of NETs are found
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in the gastroenteropancreatic system and lungs (ACS, 2013; Diebold et al., 2012; Turaga
& Kvols, 2011; Vinik et al., 2014). NETs lack definitive causative factors, but there are
genetic and behavioral factors (such as smoking) associated with the disease’s etiology
(ACS, 2013; Tsikitis et al., 2012). For example, the MEN1 gene is associated with
inherited and sporadic cases of NETs (ACS, 2013; Kulke et al., 2011; Metz & Jensen,
2008).
The tumors’ heterogeneous nature, differences from other tumors found in the
same organs, and lack of early detection methods make it difficult to diagnose and treat
NETs: over 60% of cases are diagnosed at an advanced stage of disease (ACS, 2013;
Jann et al., 2011; Modlin et al., 2008; Modlin et al., 2010; Turaga & Kvols, 2011; Van
Eeden et al., 2002). The reason that the diagnosis is so challenging is partially due to the
varying degrees of symptoms associated with the tumors. Some patients may exhibit
many symptoms, whereas others may have no symptoms at all—it depends on whether or
not the tumors overproduce certain regulatory hormones (Fröjd, Larsson, Lampic, & von
Essen, 2007; Haugland et al., 2013; Kulke et al., 2011; Modlin et al., 2008). Tumor
classification can also be complicated, and NET patients would benefit from an improved
classification system (Jann et al., 2011). Furthermore, Ӧberg and Castellano (2011) stated
that “…most patients lack access to the multidisciplinary early care necessary for optimal
management of these complex tumors” (p. S3). A more in-depth discussion of NETs
diagnosis, classification, and treatment is found in Chapter 2.
In addition to the lack of preventive methods for NETs, researchers have observed
survival rate disparities related to anatomic locations of the tumor, geographic regions,
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and race/ethnicity (ACS, 2013; Hauso et al., 2008; Lawrence, Gustafsson, Chan, et al.,
2011; Modlin et al., 2008; Ӧberg et al., 2012; Tsikitis et al., 2012). It is estimated that
there are five NET cases per 100,000 individuals in the United States annually, and the
number of cases has increased over the last 30 years (ACS, 2013; Lawrence et al., 2011;
Modlin et al., 2008; Vinik, Silva, & Vinik, 2011; Vinik et al., 2014). The prevalence is
estimated at 35 cases per 100,000 individuals (Ӧberg & Castellano, 2011). Given the
increase in incidence as well as the difficulties associated with prevention, diagnosis, and
treatment, NETs are a potential public health issue.
There are known biomarkers associated with NETs (Ardill & Erikkson, 2003;
Diebold et al., 2012; Modlin et al., 2008; Vinik et al., 2014). Each biomarker has its
strengths and limitations. For example, Chromogranin A (CgA) is considered a general
marker for NETs, but transcription factors CDX2 and TTF-1 are reliably used for midgut
NETs and pulmonary NETs, respectively (Klöppel, 2007). Ito, Igarashi, and Jensen
(2012), Lawrence et al. (2011), Modlin et al. (2010), as well as Ӧberg and Castellano
(2011) highlighted a need for specific, high-quality biomarkers for early diagnosis,
treatment, and disease management/follow-up. Biomarkers are addressed further in
Chapter 2.
Research in the field of NETs has increased, as has an interest in patient-reported
outcomes (Vinik et al., 2011; Vinik et al., 2014). This interest in patient-reported
outcomes has been bolstered by the interest in making health a “patient-centered
environment” and “…incorporating patients’ assessments of their health status” in the
field of medicine (Vinik et al., 2011, p. 99). The rise in patient-reported outcomes has led
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to more interest in health-related QOL, a multidimensional concept that reflects all
aspects of a patient’s life that contribute to her health and well-being. Nonetheless,
research about NETs and their impact on patients’ QOL is limited (Vinik et al., 2011;
Yadegarfar et al., 2013).
The Norfolk QOL-NET was developed as a NET-specific, health-related QOL
tool in 2004 (E. Vinik et al., 2009; Vinik et al., 2014). This validated 72-item instrument
can measure the “frequency and severity of symptoms” in addition to measuring eleven
common symptoms of NETs (Vinik et al., 2011, p. 100). The Norfolk QOL-NET is
comprised of seven different domains, and they are identified as follows: cardiovascular,
depression, flushing, gastrointestinal, physical functioning, positive/negative attitude, and
respiratory (E. Vinik et al., 2009). Physical functioning contributes the most to overall
QOL (E. Vinik et al., 2009). Another validated NET-specific tool was developed in
Europe, the EORTC QLQ-C30 QLQ-GINET-21 (Yadegafar et al., 2013). This tool is
comprised of two parts: the generic, 30-item cancer questionnaire (EORTC QLQ-C30)
and the 21-item, NET-specific QLQ-GINET-21 (Davies et al., 2006; Yadegarfar et al.,
2013). Additional information about the EORTC QLQ-C30 QLQ-GINET-21 is found in
Chapter 2. The secondary data analyzed in this study were collected with the Norfolk
QOL-NET instrument.
As noted previously, a small body of literature about QOL and NET research
exists. There is a need for more studies in this field because the findings could be used to
benefit patients and their caregivers as well as facilitate improved disease management
and patient care. Fröjd et al. (2007) found that NET patients had increased worries and
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higher levels of emotional distress than the general population. Similarly, Haugland et al.
(2009) observed that NET patients had impaired vitality and general health in addition to
physical limitations. In another study, Haugland et al. (2013) showed that an intervention
for NET patients helped improve QOL, particularly self-efficacy, physical functioning,
and stress levels. Other studies examining QOL and NETs are reviewed in Chapter 2.
Notably, studies with the Norfolk QOL-NET have found correlations between
tumor burden and three of the instrument’s domains: physical functioning, depression,
and gastrointestinal (Vinik et al., 2014). A significant correlation between serotonin (a
biomarker for NETs), total QOL, and the three domains (physical functioning,
depression, and gastrointestinal) was observed as well (Vinik et al., 2014). With the
EORTC QLQ-C30 QLQ-GINET-21, Korse, Bonfrer, Aaronson, Hart, and Taal (2009)
found that the universal NETs biomarker, CgA, was significantly correlated with physical
functioning and overall QOL. CgA was associated with survival time as well (Korse et
al., 2009). Combining studies about biomarkers with QOL could provide clinicians and
researchers another avenue to further improve the diagnosis, treatment, and management
of patients’ disease.
Despite the abovementioned findings, there are gaps in the literature to be
addressed. More research is warranted on the relationships between QOL (and aspects of
QOL) and major NET biomarkers. Furthermore, given the disease’s heterogeneity, there
does not appear to be sufficient information about whether the primary tumor site has an
impact on patients’ QOL. Because these remain understudied areas of NET research, this
study’s results may make a contribution to the field by further exploring the relationship
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between QOL and NETs. Per Vinik, E. et al. (2009), “consideration of a patient’s QOL
has become increasingly significant in evaluating the adverse health effects resulting
from chronic illnesses such as NETs” (p. e87). Knowledge about NETs as they relate to
patient QOL could make a positive social change by helping NET patients assess the
severity of their condition, determine what’s affecting their well-being, as well as help
monitor their progress during treatment. Caregivers and physicians for NET patients can
also benefit from this information. QOL information can connect physicians with their
patients and give them a better understanding of what’s influencing their outcomes.
Problem Statement
While other studies have shown that NET patients have diminished QOL when
compared to a general population, there are still unknowns about the relationship between
the overall QOL of NET patients and their primary tumor sites (Fröjd et al., 2007;
Haugland et al., 2009; Knox et al., 2004; Larsson, Sjödén, Ӧberg, Eriksson, & von Essen,
2001; E. Vinik et al., 2009; Vinik et al., 2011; Vinik et al., 2014; Yadegarfar et al., 2013).
Some researchers’ studies have evaluated the association between QOL and certain NET
biomarkers; however, most of these studies focused on CgA, 5-hydroxyindoleacetic acid
(5-HIAA), and serotonin (Korse et al., 2009; Larsson et al., 2001; Vinik et al., 2011;
Vinik et al., 2014). It is likely that the presence of specific biomarkers associated with
NET-related symptoms or tumor types negatively impacts patients’ QOL or even aspects
of QOL (like the cardiovascular or flushing domains in the Norfolk QOL-NET);
furthermore, different primary tumor types may have varying effects on QOL (ACS,
2013; Lawrence, Gustafsson, Kidd, et al., 2011; Haugland et al., 2013; Modlin et al.,
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2008; Vinik & Gonzales, 2011). As mentioned in previous publications, QOL acts as the
dependent variable that changes based on other factors (Stuifbergen, Seraphine, &
Roberts, 2000). This study was devised to move beyond what has been published by
examining the relationship between total QOL and patients’ primary tumor sites.
Additionally, the relationship between total QOL and six novel biomarkers of NETs (5HIAA, CgA, gastrin, Neurokinin A [NKA], pancreastatin, and serotonin) was
investigated. This study was designed to address gaps in the research literature about the
impact of NET biomarkers as well as whether the primary tumor site affects patients’
QOL.
Purpose
The purpose of this quantitative study was to determine whether there was an
association between the total QOL (dependent variable) of NET patients and their
different primary tumor sites (independent variable). The relationship between QOL and
disease-specific biomarkers was also assessed. The biomarkers were assessed as
independent variables to determine whether they affect QOL.
Research Questions and Hypotheses
The research questions and hypotheses for this study were as follows:
Research Question 1: What is the relationship between the primary tumor site and
NET patients’ total QOL score?
H01: There is no relationship between the primary tumor site and NET patients’
total QOL score.
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H11: There is a relationship between the primary tumor site and NET patients’
total QOL score.
Research Question 2: How does the presence of specific NET biomarkers (NKA,
pancreastatin, serotonin, 5-HIAA, gastrin, and CgA) affect the total QOL score for
NET patients?
H02: The presence of specific NET biomarkers (NKA, pancreastatin, serotonin, 5HIAA, gastrin, and CgA) does not affect the total QOL score for NET patients.
H12: The presence of specific NET biomarkers (NKA, pancreastatin, serotonin, 5HIAA, gastrin, and CgA) affects the total QOL score for NET patients.
Theoretical Framework
Explanatory theory, specifically the explanatory model of health promotion and
quality of life in chronic disabling conditions, was used as this study’s theoretical
framework. The National Cancer Institute (NCI, 2005) stated that explanatory theory
“…guides the search for factors that contribute to a problem” (p. 5). Through explanatory
theory, the components of a disease or health problem can be identified and later applied
to health interventions; similarly, QOL is a patient-reported outcome that is comprised of
multiple measureable domains (or components) such as social well-being and physical
functioning (Green, 2000; NCI, 2005; Vinik et al., 2014). Kleinman, Eisenberg, and
Good (1978) developed an explanatory model that underscored the importance of the way
people understand their illness and health-related experiences. Comparable to QOL,
Kleinman et al.’s (1978) explanatory model is concerned with patient-reported
perceptions of illness or health. Like explanatory theory, QOL seeks to answer the how

10
and why aspects of a disease from the patient’s point of view. A QOL study based on this
theoretical framework could help increase one’s understanding about how a disease or
condition impacts patients.
Stuifbergen et al. (2000) developed the explanatory model of health promotion
and quality of life in chronic disabling conditions. In this model, like the proposed study,
QOL was the dependent variable affected by different factors (e.g., behavioral,
contextual, and/or attitudinal) either directly or indirectly (Stuifbergen et al., 2000). This
explanatory model identified three variables (health-promoting behaviors, severity of
illness, and resources) that directly impact QOL (Stuifbergen et al., 2000). It was
reflective of the proposed study’s research questions into the effects of NET biomarkers
and primary tumor sites on the dependent variable of QOL. Furthermore, a health-related
QOL study that applied this framework could be considered the first step toward
identifying factors that could be modified to help improve QOL in future studies for NET
patients.
Nature of the Study
In this quantitative study, I analyzed secondary, de-identified clinical data that
were collected from NET patients using the Norfolk QOL-NET questionnaire. The
Norfolk QOL-NET is a validated and reliable 72-item questionnaire that measures seven
domains that impact the QOL of NET patients (E. Vinik et al., 2009; Vinik et al., 2011).
The study data were quantitative, cross-sectional, and generalizable to a NET patient
population in the same age range as the patients in the dataset. A quantitative approach
aligned with the analysis of the questionnaire-based numerical data and the problem
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statement. Data for Research Question 1 and Research Question 2 were analyzed via a
one-way analysis of variance (ANOVA) test and a post hoc test. The biomarkers and
primary tumor sites were evaluated as independent variables to determine their
relationship with total QOL scores. Total QOL was the dependent variable. Data were
also evaluated using multiple linear regression analysis for Research Question 1 and
Research Question 2.
Operational Definitions of Technical Terms
Quality of life or QOL: The overall concept of health-related quality of life unless
stated otherwise. The concept of QOL was revised to incorporate health by the World
Health Organization (WHO) after World War II (Centers for Disease Control and
Prevention [CDC], 2011; Ormel, Lindenberg, Steverink, & Vonkorff, 1997; Vinik et al.,
2011; Vinik et al., 2014). QOL is multidimensional, reflecting patients’ well-being as
well as the ways that their life experiences and illness/health conditions impact their daily
lives (CDC, 2011; E. Vinik et al., 2009).
Primary tumor site: Where the cancer originated in the body (ACS, 2013).
Biomarker: The measureable hormones and peptides that are used to help
diagnose the disease and/or identify the type of tumor as well as help determine whether
a treatment is working or the tumor has recurred (Diebold et al., 2012; Eriksson, Öberg,
& Stridsberg, 2000). A biomarker may be prognostic or predictive (Eriksson et al., 2000).
Some of the NETs biomarkers are also associated with survival (Diebold et al., 2012).
Immunohistochemistry: An analytical technique used to test for certain molecules
(e.g., biomarkers) in tissues (NCI, n.d.).
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Neuroendocrine cells: Part of the body’s diffuse neuroendocrine system. These
cells behave “…like nerve cells in certain ways and like hormone-making endocrine cells
in other ways” (ACS, 2013, p. 3). These cells regulate gut motility and are the body’s
largest group of hormone-secreting cells (Lawrence, Gustafsson, Chan, et al., 2011;
Modlin et al., 2008).
Gastroenteropancreatic system: The anatomical sites where these tumors
commonly arise in the gastrointestinal tract and pancreas, including the following: the
foregut (first duodenum, stomach, bronchi, and thymus); midgut (appendix, right colon,
ileum, second duodenum, and jejunum); hindgut (from the transverse colon to the
rectum); and the pancreas (Turaga & Kvols, 2011).
Assumptions
Assumptions were necessary for the identification of potential threats to the
study’s validity. Given that secondary data from a questionnaire were used for this study,
it was assumed that the patients who responded to the Norfolk QOL-NET answered the
questions honestly. It was assumed that the QOL data, primary tumor information, and
biomarker data were recorded accurately in the database. It was also assumed that QOL
data were collected and coded properly.
Scope and Delimitations
Based on other studies in the literature, it was believed that NETs and their related
biomarkers affected patients’ QOL. This study was conceived to fill a gap in knowledge
about the relationship between NET biomarkers, primary tumor sites, and QOL. The
secondary data were originally collected from NET patients using a validated and reliable
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NET-specific instrument. Participants were selected because they were NET patients.
Consequently, these study data were limited to adult patients with NETs ranging from 18
to 85 years of age, so the results were not generalizable to any other patient population. I
considered health belief theory and social cognitive theory, but they did not seem to fit
the multiple domain, component-like aspect of QOL like explanatory theory and the
explanatory model of health promotion and quality of life in chronic disabling conditions.
As such, they were not used in the study.
Limitations
Analytically, it was assumed that the data were normally distributed within the
independent variable, had equal variances, and were independent. As with any
questionnaire-related study, there was also concern about self-report or recall bias
affecting the results. The Norfolk QOL-NET’s reliability and validity helped avoid
instrumentation limitations. Significant findings from this study population, discussed in
Chapters 4 and 5, warrant future research in a larger study population. The differences in
the interpretation between age groups may be a limitation and are discussed further in
Chapter 5 with the interpretation of the results.
Significance of the Study
Patient-reported outcomes are important to evaluate in clinical studies (Vinik et
al., 2011; Yadegarfar et al., 2013). This study determined whether tumor sites and
biomarkers affected QOL, which may facilitate a better understanding of the disease and
its relationship to patient-reported outcomes; ultimately, this information could contribute
to positive social change in the field. This study could be one of the first to demonstrate
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an association between novel biomarkers for NETs (other than serotonin) and QOL. This
information could benefit professional practice by influencing decision-making
approaches to treatments for NETs over time. Additionally, results from studies that use
instruments such as the Norfolk QOL-NET could be used to develop interventions or
patient education programs that can reduce the effects of symptoms and disease-related
stress as well as improve self-efficacy, physical functioning, and total QOL for this
population (Haugland et al., 2013). These types of interventions could have a significant
positive impact on the NET patient population and their caregivers.
Summary
The field of NET research is growing, leading to a deeper understanding of this
heterogeneous disease and its biomarkers. Researchers have shown that NET biomarkers
can have a unique impact on the disease, from its presentation to symptom manifestation
and even disease survival (Ardill & Erikkson, 2003; Diebold et al., 2012; Ito et al., 2012;
Lawrence, Gustaffson, Kidd, et al., 2011; Modlin et al., 2008; Modlin et al., 2010; Ӧberg
& Castellano, 2011; Turaga & Kvols, 2011; Vinik et al., 2014). There is also an increased
interest in NETs and QOL—this research could further the understanding of various
factors that impact patients’ QOL. Despite the growing interest in the topic, there is still a
need for additional studies that delve further into how NETs affect patients’ QOL. In this
study, I aimed to fill that gap by determining whether there was a relationship between
QOL and different primary tumor sites. I also investigated the relationship between
novel, disease-specific biomarkers and QOL for patients with NETs. Ultimately,
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combining aspects of QOL research with tumor-specific research could help provide a
more complete picture of the disease and its impact on patients.
Chapter 2 includes an overview of the literature relevant to this research,
including information about the study framework, NETs, NET-related biomarkers, as
well as NETs and QOL. In Chapter 3, I address this study’s research design, the Norfolk
QOL-NET instrument, and statistical analyses. Chapter 4 includes the results from the
analyses as they pertain to the research questions and hypotheses. In Chapter 5, I present
an interpretation of the study’s findings along with implications for social change and
recommendations for action/future studies.
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Chapter 2: Literature Review
Introduction
The purpose of this study was to examine the relationship between total QOL and
patients’ primary tumor sites. Additionally, the relationship between total QOL and six
novel biomarkers of NETs (5-HIAA, CgA, gastrin, NKA, pancreastatin, and serotonin)
was investigated. This literature review affirmed the need to address the unknowns about
the relationship between the QOL of NET patients with different primary tumor sites and
six novel biomarkers of the disease. While research about NETs and interest in patientreported outcomes have increased over the last decade, QOL as it relates to this type of
cancer is a young field (Vinik et al., 2011; Yadegarfar et al., 2013). Results from the
literature review demonstrated that the body of literature about QOL and NETs is not
extensive. It further emphasized the gap of knowledge about QOL, NETs, and
biomarkers in this field. Although there is substantial information about established NET
facts in the literature, there are still many unknowns (including the molecular
mechanisms of this heterogeneous disease and the role of certain biomarkers). Modlin et
al. (2008) commented that the field of NETs is underfunded, which likely contributes to
the smaller body of research. Given that the field of NET research is growing, results
from this study could potentially make a noteworthy contribution to the field.
This chapter includes an overview of NETs, including primary tumor sites,
epidemiology, biomarkers, and their relationship to the disease. A discussion of QOL as
it relates to NETs is also included. The Norfolk QOL-NET as well as the European NETspecific instrument, the EORTC QLQ-C30 QLQ-GINET21, are also described in this
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chapter. A summary of QOL and NET research studies that used either generic or
disease-specific instruments is presented. The literature search strategy is discussed along
with the theoretical framework (explanatory model of health promotion and quality of life
in chronic disabling conditions) and its relationship to this study as well.
Literature Search Strategy
For this research, a literature search was conducted online using electronic
databases including PubMed, Google Scholar, Google, and Walden University’s library.
For the chapter’s theoretical framework section, search terms included explanatory
theory with origin, definition, health, quantitative study, quality of life, or health model.
Other search terms included neuroendocrine tumors along with one of the following:
QOL, QOL-NET, EORTC QLQ-GINET21, NKA, pancreastatin, serotonin, 5-HIAA,
gastrin, and CgA. All of the peer reviewed articles and book chapters were obtained
digitally. The scope of literature ranged from 1978 to the present. Older peer reviewed
sources were used for historical content, while peer reviewed sources published within
the last decade were used as the focus of the literature review. Two books were used as
sources because they contained relevant information about biochemical measures and
NETs. Peer reviewed sources were selected based on their relevance to the proposed
study.
Theoretical Framework
The theoretical framework applied to this research was explanatory theory,
specifically the explanatory model of health promotion and quality of life in chronic
disabling conditions. Explanatory theory’s foundation is in factors that determine health
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and health behaviors—as a theory, it can help investigators answer the why questions of
health problems (Green, 2000; NCI, 2005). Other theories in health promotion are
considered explanatory theories, including the theory of planned behavior and the health
belief model (NCI, 2005). Explanatory theory allows for the identification of a disease or
problem’s components that could be addressed by future interventions (Green, 2000;
NCI, 2005). Similarly, health-related QOL is a patient-reported outcome comprised of
multiple measurable domains (e.g., physical and psychological functioning), and
knowledge about patient-reported QOL can help determine what factors need to be
addressed to improve one’s health and well-being (Vinik et al., 2014). Explanatory theory
has been applied to QOL-related research before, but not as it relates to NET studies. It
is, however, supportive of the multidimensional concept of health-related QOL.
Patient-reported QOL is a multidimensional construct (Cummins, 2005; Vinik et
al., 2011; Vinik et al., 2014). As such, it is well-suited to an explanatory theory-related
framework because it looks at components that help answer the how, why, and what
factors of a condition or disease from the patient perspective. A QOL study rooted in this
theoretical framework can help increase one’s understanding about how a disease or
condition impacts patients. Furthermore, a health-related QOL study that applied an
explanatory theory as a framework could be considered the first step toward identifying
factors that could be modified to improve health-related QOL in future studies.
Some investigators used explanatory theory to develop explanatory models. One
of these models is Kleinman et al.’s (1978) explanatory model of illness. It is an
important model that describes how people understand their illness and related
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experiences (Kleinman et al., 1978). Much like QOL, the explanatory model of illness is
comprised of patient-reported perceptions of their health/illness. Explanatory theory itself
has not been widely applied to QOL research, but there are studies that incorporate these
concepts. Cummins (2005) identified a need for a testable theory for QOL and proposed
that conceptual models of QOL (with indicator and causal variables) could transition to
explanatory theory.
Stuifbergen et al. (2000) developed an explanatory model of QOL based on
findings from quantitative and qualitative studies in the literature. In their explanatory
model, they determined that QOL is shaped directly and indirectly by different factors
(e.g., behavioral, contextual, and/or attitudinal; Stuifbergen et al., 2000). This model also
assumes that QOL changes over time along with an individual’s illness or health status
(Stuifbergen et al., 2000). In this model, like this study, QOL is the dependent variable
affected by other independent variables (Stuifbergen et al., 2000). Additionally, this
explanatory model identifies three variables (health-promoting behaviors, severity of
illness, and resources) that directly impact QOL (Stuifbergen et al., 2000). Results from a
study in a large population with multiple sclerosis supported Stuifbergen et al.’s (2000)
explanatory model of QOL, and the authors observed that the factors that impact QOL
would be useful targets for interventions for a population with a chronic disabling
condition. Phillips’ (2005) analysis of Stuifbergen et al.’s (2000) model concluded that it
is valuable “…to expand the knowledge base of nurses and other professionals” as well
as to help patients with chronic conditions (p. 22). This model is appropriate because it
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mirrored the proposed study’s research questions that evaluated the effects of NET
biomarkers and primary tumor sites on the QOL of NET patients.
Neuroendocrine Tumors
Neuroendocrine Tumors and their Primary Tumor Sites
The first NETs were identified at different points in the latter half of the 19th
century by three pathologists: Theodor Langhans, Otto Lurbarsch, and William Ransom
(Hauso et al., 2007; Ӧberg & Castellano, 2011). These tumors were further described in
the early 1900s by Siegfried Oberndorfer—he coined the term karzinoide in 1907 and
later defined malignant NETs in 1929 (Modlin et al., 2008; Turaga & Kvols, 2011; Van
Eeden et al., 2002). Pierre Masson and Andre Gosset elaborated on the endocrine nature
of carcinoid tumors in 1914 (Hauso et al., 2008; Van Eeden et al., 2002).
NETs are rare, slow progressing, heterogeneous tumors that arise in cells in the
body’s widely-dispersed neuroendocrine system or diffuse endocrine system (ACS, 2013;
Haugland et al., 2013; Klöppel, 2007; Ӧberg, Knigge, Kwekkeboom, & Perren, 2012;
Prestifilippo, Blanco, Vitalo, & Giuffrida, 2012; Tsikitis et al., 2012; Vinik et al., 2014).
ACS (2013) noted that these cells exhibit similarities to hormone-producing endocrine
cells as well as nerve cells and can be found throughout the body. According to Modlin et
al. (2008), neuroendocrine cells are “…the largest group of hormone-producing cells in
the body” (p. 62). This wide-dispersion is the reason why there are multiple primary
tumor sites for this type of cancer. NETs can be found throughout the body, particularly
in the pancreas, gastrointestinal system (appendix, intestines, ileum, stomach, colon, and
rectum), and lungs (ACS, 2013; Mayo Clinic, 2013; Vinik et al., 2014). In the
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gastroenteropancreatic system, NETs are more common in the small intestine, especially
the ileum (ACS, 2013; Diebold et al., 2012; Turaga & Kvols, 2011). They are also
common in the jejunum (Diebold et al., 2012).
Causes of NETs. The causes of NETs are still unknown. Some inherited and
sporadic cases of NETs are related to mutations in the MEN1 gene (ACS, 2013; Kulke et
al., 2011). Over 80% of patients with MEN1 mutations will develop pancreatic NETs
(Metz & Jensen, 2008). It has been estimated that 10% of gastrointestinal NETs are the
result of an inherited mutation in the MEN1 gene (ACS, 2013). There are also inherited
cases of NETs in the small intestines that are related to mutations in the NF1 gene (ACS,
2013; Kulke et al., 2011). Pernicious anemia and low acid states are associated with type
1 gastric carcinoids (Lawrence, Gustafsson, Chan, et al., 2011). Individuals with von
Hippel-Lindau syndrome (VHL) and tuberous sclerosis complex (TSC) are at an
increased risk for NETs as well (ACS, 2013; Ӧberg et al., 2012; Kulke et al., 2011). A
different mutation in the VHL gene has been related to VHL-associated
gastroenteropancreatic NETs (Turaga & Kvols, 2011). Metz and Jensen (2008) reported
that individuals with MEN1 disorder, VHL, TSC, or NF1 have an increased incidence of
developing pancreatic NETs. Approximately 11%-17% of individuals with VHL will
develop a pancreatic NET (Turaga & Kvols, 2011).
The majority of NET cases appear to occur because of sporadic mutations in
tumor suppressor genes or oncogenes; nonetheless, there are insufficient data about
neuroendocrine tumorigenesis (ACS, 2013; Metz & Jensen, 2008; Modlin et al., 2008;
Turaga & Kvols, 2011). Modlin et al. (2008) observed that preclinical studies related to
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NET pathogenesis (e.g., in cell lines and animal models) “…have had substantial
limitations” and “…have not successfully translated to the clinic” (p. 63). There have
been rodent studies with promising results, but a lack of genomic information limited
them (Modlin et al., 2008). There is also a dearth of human neuroendocrine cell lines
(Modlin et al., 2008). Research on deoxyribonucleic acid (DNA) microarrays for NET
gene expression profiles is underway, but nothing has been validated yet (Turaga &
Kvols, 2011).
Diagnosis, classification, and treatment. The tumors’ heterogeneous nature
makes them a challenge to diagnose and treat (Jann et al., 2011). NETs are different from
other types of tumors found in the same organs, and there are no methods for early
detection (ACS, 2013; Ӧberg & Castellano, 2011). As such, delayed diagnosis after the
tumors have metastasized is common—it is estimated that 60%-80% of patients have
metastatic NETs when diagnosed (Modlin et al., 2008; Modlin et al., 2010; Turaga &
Kvols, 2011; Van Eeden et al., 2002). Sometimes, diagnosis can be delayed as long as 57 years or more (Modlin et al., 2008; Ӧberg & Castellano, 2011). Survival increases if
diagnosis occurs prior to metastases, highlighting the need for more sensitive and specific
imaging techniques as well as the development of new biomarker assays to better
diagnose NETs (Ӧberg & Castellano, 2011; Vinik et al., 2011).
NETs may be considered functional (meaning that they actively secrete hormones
or peptides) or nonfunctional. Functional tumors are usually diagnosed before
nonfunctional cases because of the related symptoms. Different imaging modalities (e.g.,
positron emission tomography scan, computerized tomography scan, or MRI) may be
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used to help diagnose the cause of symptoms (ACS, 2013; Ӧberg & Castellano, 2011).
NETs may also be detected by endoscopy, colonoscopy, blood/urine tests for certain
biomarkers, or biopsies, depending on the symptoms, clinical suspicions, and/or the
clinician (ACS, 2013; Ӧberg & Castellano, 2011). NET-related symptoms are the result
of the overproduction of regulatory hormones, amines, or vasoactive peptides secreted by
the tumors, and they can differ on a case by case basis (Haugland et al., 2013; Kulke et
al., 2011; Modlin et al., 2008; Ӧberg & Castellano, 2011). Individuals can be completely
asymptomatic, indicating that their tumor is probably nonfunctional, whereas others may
have functional tumors that secrete hormones or peptides, causing severe symptoms
(ACS, 2013; Haugland et al., 2013; Modlin et al., 2008). Symptoms such as diarrhea,
flushing, and wheezing are related to hormones released by the tumors (ACS, 2013;
Haugland et al., 2013). Some of the hormones released by certain NETs can damage the
heart and result in carcinoid heart disease (ACS, 2013). Dobson et al. (2013) observed
that carcinoid heart disease “…has prognostic significance for long-term survival” (para.
3). A combination of certain symptoms in NET patients (diarrhea, flushing, and heart
disease) is referred to as carcinoid syndrome (Ӧberg & Castellano, 2011). Other clinical
syndromes can result from the expression of these substances, including Verner Morrison
syndrome (vasoactive intestinal peptidoma), Zollinger-Ellison syndrome (ZES;
gastrinoma), hypoglycemia, and WDHA syndrome (watery diarrhea hypokalemia, and
achlorhydria; Ӧberg & Castellano, 2011). These hormones and peptides are considered
biomarkers of the disease—they are discussed later in the chapter.
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Classification of NETs is complicated and difficult; yet, it can be critical for
patients’ disease management and survival. Despite the clinicopathological heterogeneity
of the tumors, there are physical similarities that result in them being grouped together,
such as cell structure and secretory granules (Ӧberg & Castellano, 2011; Prestifilippo et
al., 2012). For example, pancreatic NETs share similar features with gastrointestinal
NETs, but there are distinct differences in the diagnosis, management/treatment, and
proposed pathogenesis of the tumors (Metz & Jensen, 2008).
Gastroenteropancreatic NETs were divided into hindgut (rectum and colon),
midgut (appendix, caecum, distal duodenum, ileum, and jejunum), and foregut (proximal
duodenum, liver, pancreas, stomach, and upper jejunum) classifications in 1963 (Klöppel,
2007; Ӧberg & Castellano, 2011). These classifications are still applicable today. They
are also categorized as “poorly differentiated neuroendocrine carcinomas” or “welldifferentiated neuroendocrine tumors” (Klöppel, 2007, p.15). Of the
gastroenteropancreatic NETs, those of the midgut are the most common, presenting with
vague symptoms that have delayed diagnosis for up to 10 years (Diebold et al., 2012).
NETs of the lung are either referred to as “small/large-cell neuroendocrine carcinomas”
or “carcinoid” (Klöppel, 2007, p. 15). Additionally, “…moderately differentiated
neuroendocrine tumors in the stomach, intestine, appendix, rectum, and lung” may be
described as “carcinoid tumors” (ACS, 2013, p. 4). There are subtypes within each organspecific type of NET as well (Klöppel, 2007).
Improving tumor classification so it is a prognostically valuable process would be
beneficial for NET patients (Jann et al., 2011). Previously, tumors were staged based on
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metastases only: local, regional, and distant (ACS, 2013). More recently, staging is done
using the American Joint Committee on Cancer’s tumor-node-metastasis (TNM) system
(ACS, 2013). Staging is completed using information about the tumor’s size, the amount
the tumor spread to regional lymph nodes, and metastases to other organs (ACS, 2013).
There are additional details measured within each level of TNM (ACS, 2013). Related,
Jann et al. (2011) noted that staging NETs using the European NET Society’s (ENETS)
proposed TNM classification system “…was a valid predictor of long-term outcome” for
patients and has “…predictive value for the prognostic stratification of these patients” (p.
3333). The ENETs-TNM system incorporates metastatic disease, tumor size/thickness,
and lymph node involvement (Turaga & Kvols, 2011). Jann et al. (2011) conducted one
of the first validation studies of the ENETS-TNM system in a European population of
270 patients with gastroenteropancreatic NETs (primary tumors in the midgut and
hindgut). Results showed that the ENETS-TNM classification system was valid for the
prognostic stratification of the study population’s NETs (Jann et al., 2011). This
classification system discriminated between local, locoregional, and advanced stage
disease in a prognostically relevant, statistically significant manner (Jann et al., 2011).
The WHO published an updated classification of NETs in 2000, 2004, and 2010
(Ӧberg & Castellano, 2011). The WHO classification divides the tumors into welldifferentiated NETs, well-differentiated neuroendocrine carcinomas, and poorly
differentiated neuroendocrine carcinomas (Ӧberg & Castellano, 2011). Ӧberg and
Castellano (2011) stated that “although the new WHO classification is an important step
towards defining the diverse tumor biology of NETs, further efforts are necessary to
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improve the prognostic assessment of each individual NET” (p. S4). This classification
system was described as favored by clinicians, but also “time-consuming” because of the
pathological examination required for the diagnosis (Ӧberg & Castellano, 2011).
Currently, treatment is based on a patient’s symptoms and tumor burden (Modlin
et al., 2008). Modlin et al. (2008) stated that “the best therapeutic choice for individual
patients will depend on whether the main aim of treatment is to slow tumour growth or
ameliorate symptoms by inhibition of the secretion of bioactive agents” (p. 67). The
primary NET treatments include surgery, chemotherapy (e.g., cisplatin, doxorubicin, 5fluorouracil, capecitabine, or etoposide), and radiation (ACS, 2013; Modlin et al., 2008).
Ablation or embolization may be an option for patients with tumors that have
metastasized to their livers (ACS, 2013). Surgery can prolong survival and may be
curative for patients with early stage tumors (Kulke et al., 2011; Modlin et al., 2008).
Although surgery may prolong survival for patients with advanced disease, other NETrelated complications (such as hormone secretion) can contribute to patient’s mortality
(Kulke et al., 2011). Furthermore, chemotherapy drugs are not always effective for NET
patients, emphasizing the need for more targeted treatments for this heterogeneous
disease (Modlin et al., 2008). New therapies, like peptide receptor radiotherapy, are being
evaluated (Kulke et al., 2011). Kulke et al. (2011) mentioned that clinical trial design can
be challenging because of the “unique characteristics” presented by NETs; however,
some promising treatments exist and are being evaluated, including mammalian target of
rapamycin (mTOR) inhibitors, somatostatin analogs, vascular endothelial growth factor
(VEGF) pathway inhibitors, and temozolomide (p. 938).
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Risk Factors and Epidemiology
While there is a lack of causative factors for NETs, researchers have identified
risk factors for this heterogeneous disease, including genetic markers (discussed
previously), age (older than 60 years of age), smoking, and race (African American;
ACS, 2013; Tsikitis et al., 2012). For unknown reasons, these tumors also appear to be
more common in women than men in the United States (ACS, 2013). Of note, NET data
from Europe showed that men have a slightly higher incidence of NETs than women
(Ӧberg et al., 2012). With regards to NETs, Lawrence, Gustafsson, Chan, et al.’s (2011)
noted that “there is a distinct epidemiologic profile for each primary site” (p. 16).
The incidence of NETs in the United States has increased over the last 30 years,
but it is unclear why this is happening (ACS, 2013; Lawrence, Gustafsson, Chan, et al.,
2011; Modlin et al., 2008; Tsikitis et al., 2012). The increase in incidence could have
occurred because of greater disease awareness, more diagnostic scans for other issues
(such as colonoscopies and endoscopies), improved immunohistochemical serodiagnostic
testing, or the actual occurrence of more cases (ACS, 2013; Hauso et al., 2008;
Lawrence, Gustafsson, Chan, et al., 2011; Modlin et al., 2008). In Caucasian and African
American populations in the United States, Modlin et al. (2008) reported a 460% and
720% increase (respectively) in NET incidence over a 30-year period. Currently, it is
estimated that there are 5 NET cases per 100,000 individuals in the United States
annually (Vinik et al., 2011; Vinik et al., 2014). The prevalence is estimated at 35 cases
per 100,000 individuals (Ӧberg & Castellano, 2011). Lawrence, Gustafsson, Chan, et al.
(2011) pointed out that gastroenteropancreatic NETs have a higher prevalence “…than
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that of most gastrointestinal cancers, including pancreatic, gastric, esophageal, and
hepatobiliary carcinomas, and is only exceeded by that of colorectal neoplasia” (p. 1).
Lawrence, Gustafsson, Chan, et al.’s (2011) epidemiologic study analyzed
Surveillance, Epidemiology and End Results (SEER) data (1973-2007) from 49,012
patients with NETs. They also found an increase in the incidence of NETs, particularly
gastroenteropancreatic NETs (Lawrence, Gustafsson, Chan, et al., 2011). Their study
found a notable increase in small intestinal and rectal NETs (Lawrence Gustafsson, Chan,
et al., 2011). Other studies, like Tsikitis et al. (2012), had similar results. Lawrence,
Gustafsson, Chan, et al. (2011) observed that it is likely that the increase in endoscopies
and other diagnostic modalities (e.g., colonoscopies) has contributed to the growing
incidence rates.
In a retrospective analysis, Tsikitis et al. (2012) examined trends in the incidence
and survival of gastrointestinal NETs in the United States (from 1973-2008) using data
on 19,669 individuals from the SEER database. Notably, over the 35-year time period,
NETs in all gastrointestinal sites (except the appendix) increased significantly across all
regions of the United States (Tsikitis et al., 2012). In their study, the authors found that
most of the tumors arose in the small intestine (n = 7,181) and rectum (n = 6,796) than
other sites (Tsikitis et al., 2012). Women had significantly higher rates of NETs in the
colon, appendix, and stomach than men (Tsikitis et al., 2012). Tsikitis et al. (2012) also
found that NETs in the colon, small intestine, and stomach were significantly more
common in individuals older than 60 years of age than NETs in the rectum and appendix.
They also found a racial disparity in the incidence of NETs in the rectum (Tsikitis et al.,
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2012). Of note, individuals whose primary tumor site was the appendix or rectum
appeared to have a better prognosis than others (Tsikitis et al., 2012). Their analysis of
survival data showed that patients with NETs in the rectum or appendix had the best
survival rates as well (Tsikitis et al., 2012).
In another study, Hauso et al. (2008) compared NET data (1993-2004) from the
SEER database and Norwegian Registry of Cancer (NRC) to ascertain whether there was
a difference in disease epidemiology on a global scale. Given the primarily Caucasian
population of Norway, the subset of SEER data on Caucasian NET patients was
compared to Norwegian NET patients (Hauso et al., 2008). Separately, the researchers
compared the SEER Caucasian and African American NET patients over the same
timeframe (Hauso et al., 2008). Results from this study showed that Caucasians from the
SEER database had a 37% higher incidence rate of NETs than those from the NRC,
largely due to higher rates of bronchopulmonary and rectal NETs in the United States
(Hauso et al., 2008). However, the overall incidence rate of NETs was found to be
increasing faster in Norway than the United States (Hauso et al., 2008). Hauso et al.
(2008) also confirmed that there is a higher incidence of NETs in African Americans in
the United States than Caucasians. In particular, African Americans had significantly
higher incidence rates of rectal and small intestinal NETs than Caucasians (Hauso et al.,
2008).
The 5-year survival rates for NET patients vary, depending on the primary tumor
type and the extent of metastases. These rates do not appear to have improved much for
gastroenteropancreatic NETs (Lawrence, Gustafsson, Chan, et al., 2011). ACS (2013)
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listed the 5-year survival rates (1988-2004) for gastrointestinal NETs in the United States
as follows: 73% (localized) to 25% (distant metastases) for stomach NETs; 68%
(localized) to 46% (distant metastases) for duodenum NETs; 65% (localized) to 54%
(distant metastases) for jejunum/ileum NETs; 88% (localized) to 25% (distant
metastases) for appendix NETs; 85% (localized) to 14% (distant metastases) for colon
NETs; and 90% (localized) to 24% (distant metastases) for rectal NETs. Turaga and
Kvols (2011) as well as Modlin et al. (2008) reported that the overall 5-year survival rate
for small intestinal carcinoids is 60% and has not changed much since the 1970s. Modlin
et al. (2008) reported that “…overall 5-year survival for pancreatic NETS varies from
97%...” to 30%, depending on the tumor subtype and degree of metastases (p. 62).
Tsikitis et al. (2012) noted that the 5-year survival rate for patients with colon NETs has
improved significantly since the 1970s—this may be due to an increase in colonoscopies.
Ӧberg and Castellano (2011) observed that studies using the updated WHO classification
for NETs have found that well-differentiated NETs have a better prognosis when
compared to well- and poorly-differentiated neuroendocrine carcinomas. Lawrence,
Gustafsson, Chan, et al. (2011) also indicated that poorly differentiated
gastroenteropancreatic NETs are more aggressive and associated with a shorter survival
time.
Neuroendocrine Tumors and Biomarkers
Researchers have not yet elucidated the molecular mechanisms of NETs, but it
appears that the tumors are genetically distinct (Gilbert et al., 2010; Klöppel, 2007;
Zhang et al., 2007). Modlin et al. (2008) stated, “The mechanisms that underlie

31
differentiation of cells of the diffuse endocrine-cell system are poorly understood” (p.
62). Like other types of cancers, there are biomarkers that contribute to the diagnosis of
NETs, disease prognosis, monitoring, tumor pathology, clinical presentation, and
treatment outcome of the disease (Ardill & Erikkson, 2003; Diebold et al., 2012; Modlin
et al., 2008). Biomarkers can be measured in the patients’ urine and/or blood plasma
(Diebold et al., 2012). The use of radioimmunoassays for NET peptide hormones began
in the mid-1960s and has expanded since then (Eriksson, Ӧberg, & Stridsberg, 2000).
Finding a single, high-quality biomarker for NETs has been challenging because of their
heterogeneous nature (Lawrence, Gustafsson, Kidd, et al., 2011). There are several
biomarkers that are commonly used to differentiate between gastrointestinal NETs and
pulmonary NETs in addition to those that act as general biomarkers of the disease. Many
of the biomarkers that have been evaluated are related to secretory vesicles or located in
the cytosol (Turaga & Kvols, 2011). Some examples are provided in the following
paragraphs.
Neuron-specific enolase (NSE) is a cytosolic marker of the disease, but it is
limited as a diagnostic biomarker because it has been found in non-NET tissues (Klöppel,
2007). Similarly, the neural cell adhesion molecule (NCAM), a cell membrane
biomarker, is found in NET cells, but it is also detectable in some normal tissues
(Klöppel, 2007; Turaga & Kvols, 2011). Synaptophysin, expressed separately from other
NET biomarkers, is a small vesicle-associated marker (Klöppel, 2007; Turaga & Kvols,
2011). CgA is a universal biomarker for NETs and is discussed in-depth later in this
chapter (Klöppel, 2007). CDX2, a transcription factor, is a reliable biomarker for midgut
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NETs and shows promise for identifying pancreatic, rectal, and lung NETs (Klöppel,
2007). Other transcription factors have a role as well. Protein atonal homolog 1,
neurogenin-3, and neuroD are involved in neuroendocrine cell differentiation, although
the mechanisms that initiate differentiation are not well understood (Modlin et al., 2008;
Turaga & Kvols, 2011). Another transcription factor, TTF-1, can be used as a marker for
lung NETs (pulmonary carcinoid and poorly-differentiated neuroendocrine carcinoma
subtypes; Klöppel, 2007). At least five somatostatin receptors have been identified as
NET markers as well (Klöppel, 2007). These five receptors are generally overexpressed
in gastroenteropancreatic NETs, specifically sst2 (Ӧberg & Castellano, 2011). As such,
somatostatin analogues are beneficial therapeutic options for the management of
functional gastroenteropancreatic NETs (Ӧberg & Castellano, 2011). Growth factors also
seem to affect carcinoid progression (Zhang et al., 2007).
Despite the established knowledge about NET-related biomarkers, Ӧberg and
Castellano (2011) identified “…an unmet need for more sensitive biomarkers for
diagnosis and follow-up” (p. S3). There is a need to further characterize genes related to
NETs for the development of molecular diagnostic screening tests (Ӧberg & Castellano,
2011). Ito et al. (2012) and Modlin et al. (2010) commented on the lack of biomarkers for
the early diagnosis and management of NETs. Ito et al. (2012) also cited the need for
biomarkers that can identify nonfunctional tumors. Research toward diagnostic markers
and treatment targets is ongoing. Gilbert et al. (2010) pointed out that anti-cancer
therapies, such as protein kinase inhibitors, can drive the search for NET biomarkers. The
authors identified Hsp90, IGF1R, and EGFR as potential molecular targets for NETs,
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indicating that further research was necessary because these could be anti-cancer targets
for future NET treatments (Gilbert et al., 2010). Zhang et al. (2007) evaluated whether
VEGF has a role in NET development and progression. Results from their in vivo study
in xenograft mouse models indicated that VEGF expression was elevated in tumors and
inhibited when treated with bevacizumab (Zhang et al., 2007). Moreover, they observed
that VEGF expression was correlated with a transcription factor, Sp1, and there was an
association between VEGF and metastases (Zhang et al., 2007).
The studies discussed in the previous paragraph illustrate the importance of
understanding the effects of biomarkers on NETs. A broader knowledge base about
biomarkers and their relationship with NETs could help clinicians optimize patients’
disease management. This research focused on six novel biomarkers of the disease as
they relate to QOL: CgA, gastrin, NKA, pancreastatin, serotonin, and 5-HIAA. These
biomarkers and related studies are discussed in the sections that follow.
Chromogranin A. CgA is probably the most widely studied NET biomarker
(Ardill & Erikkson, 2003; Eriksson et al., 2000; A. Vinik et al., 2009). The CgA protein
is an acidic glycoprotein found in normal neuroendocrine cells and NET cells’
neurosecretory vesicles—it is frequently detected in 60%-100% of NET patients’ plasma
(Kulke et al., 2011; Prestifilippo et al., 2012; Turaga & Kvols, 2011; Vinik & Gonzales,
2011). CgA is a precursor to peptides such as pancreastatin, and it fosters the creation of
dense-core secretory granules in NET cells (Klöppel, 2007; Modlin et al., 2008;
Prestifilippo et al., 2012). Plasma CgA is considered a useful marker for functional and
nonfunctional pancreatic NETs (Ito et al., 2012; Metz & Jensen, 2008; Ӧberg et al.,

34
2012). Additionally, CgA is secreted in gastrointestinal NETs of the hindgut, midgut, and
foregut as well as other tumor subtypes (Prestifilippo et al., 2012). Per Kulke et al.
(2011), “elevated plasma CgA levels have been associated with poor overall prognosis in
patients with NETs” (p. 940). It is a particularly useful biomarker for advanced disease
and tumor recurrence as well (Seregni, Ferrari, Bajetta, Martinetti, & Bombardieri, 2001;
Modlin et al., 2010). While Lawrence, Gustafsson, and Kidd, et al. (2011) commented
that “the clinical utility of this tool is blunted…by the ubiquity of CgA in normal tissue,”
they also acknowledged that it is an important biomarker for diagnosing and managing
gastroenteropancreatic NETs (p. 111).
CgA can be applied as a broad-spectrum diagnostic marker, used to assess
treatment effectiveness, and act as a follow-up marker because it sensitive for NETs
(Lawrence, Gustafsson, Kidd, et al., 2011; Ӧberg & Castellano, 2011; Prestifilippo et al.,
2012; Turaga & Kvols, 2011). Toward the detection of NETs, CgA’s sensitivity and
specificity ranges from 70%-100% (Seregni et al., 2001; Vinik & Gonzales, 2011).
Modlin et al. (2010) called it a “sensitive but nonspecific” NET biomarker (p. 2432).
Studies have shown that it is more sensitive biomarker than either platelet serotonin or
urinary 5-HIAA as well (Modlin et al., 2010).
Kulke et al. (2011) observed that plasma CgA measurements should be included
in prospective clinical trials, even though it is not validated as a predictive biomarker.
Despite its strengths, Ito et al. (2012) pointed out that there is conflicting literature about
whether serum CgA is useful as a biomarker for tumor growth or management. CgA
levels are affected in patients who regularly take proton pump inhibitors as well as in
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patients with liver failure, renal failure, or chronic gastritis (Eriksson et al., 2000; Ito et
al., 2012; Vinik & Gonzales, 2011).
Gastrin. Gastrin is another biomarker of the disease that contributes to the
pathogenesis of gastric NETs (Burkitt, Varro, & Pritchard, 2009; Klöppel & Clemens,
1996). Gastrin is a peptide hormone that regulates the production and secretion of gastric
acid as well as regulates the expression of gastric CgA via transcriptional mechanisms
(Hocker, 2004). It is a diagnostic biomarker for gastric NETs and can be used to
distinguish between subtypes of gastric carcinoids (Burkitt et al., 2009; Vinik &
Gonzales, 2011). Furthermore, gastrin can be a biomarker for NETs in the bronchus,
pancreas, stomach, and duodenum (Modlin et al., 2008). In a historic paper, Bostwick,
Roth, Evans, Barchas, and Bensch (1984) found gastrin-releasing peptide in a sample of
human lung neuroendocrine tumors. It is also a biomarker associated with NETs-related
diarrhea and ZES (Burkitt et al., 2009; A. Vinik et al., 2009).
Neurokinin A. Recent studies have shown that NKA, a tachykinin, is a beneficial
prognosis marker for patients with well-differentiated midgut NETs, the most common
type of gastroenteropancreatic NETs (Ardill & Erikkson, 2003; Diebold et al., 2012;
Dobson et al., 2013; Mamikunian et al., 2011). Modlin et al. (2008) previously stated that
NKA can be a biomarker for NETs in the ileum at intermediate specificity. Turner et al.’s
(2006) evaluation of 139 patients with midgut NETs confirmed that plasma NKA is an
independent prognostic marker, making it one of the first studies to identify NKA’s
ability to predict survival. NKA can be applied as a marker for individuals with poor
prognosis and used to identify patients who need changes in their treatment to improve
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survival (Diebold et al., 2012; Mamikunian et al., 2011). NKA is also one of the
biomarkers for flushing related to NETs and possibly carcinoid heart disease (A. Vinik et
al., 2009; Dobson et al., 2013).
A comparison of two NKA assays using plasma samples from patients in the
United Kingdom and United States showed promising results for the biomarker (Diebold
et al., 2012; Mamikunian et al., 2011). Mamikunian et al. (2011) performed the crossvalidation of these two methodologically different, validated assays. Results from the
regression analysis of the NKA values indicated a statistically significant high degree of
correlation between the two populations (Mamikunian et al., 2011). This cross-validation
indicated that the reliability of these assays’ ability is able to predict clinical outcomes as
well as a level of equivalence, which is beneficial for future collaborative studies
(Mamikunian et al., 2011).
Research also demonstrated that lower “…circulating plasma levels of NKA are
associated strongly with enhanced survival” (Diebold et al., 2012, p. 1173). Patients with
a NKA level less than 50 pg/mL had a much higher 3-year survival rate (65%) than those
with NKA levels greater than 50 pg/mL (10%; Diebold et al., 2012; Mamikunian et al.,
2011). Of note, patients that had NKA levels that were reduced by treatment returned to a
survival rate similar to NKA patients that never had a higher level of the marker (Diebold
et al., 2012; Mamikunian et al., 2011).
Based on the above information, Diebold et al. (2012) compared short-term
survival of patients with midgut NETs who had consistently higher (> 50 pg/mL) and
lower (< 50 pg/mL) NKA levels. They found that the serial measurement of NKA in
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patients with well-differentiated midgut NETs was able to identify patients with “…a
poor short-term prognosis if left untreated” (Diebold et al., 2012, p. 1175). Furthermore,
they also found that patients with higher NKA levels that dropped after treatment had
improved survival (Diebold et al., 2012). The investigators concluded that NKA is a
sensitive biomarker for monitoring therapy effectiveness (Diebold et al., 2012).
Pancreastatin. Pancreastatin is a post-translational peptide product generated
from CgA and present in NETs (Ito et al., 2012; Vinik & Gonzales, 2011). Unlike CgA, it
is not affected by patients taking proton pump inhibitors (Ito et al., 2012). It has been
shown “…to be a sensitive indicator of progressive disease” in midgut NETs more
recently (Diebold et al., 2012, p. 1172). High levels of plasma pancreastatin (greater than
500 pmol/L) are associated with poor outcome/survival in NET patients (A. Vinik et al.,
2009; Vinik & Gonzales, 2011). Pancreastatin is achieving acceptance as a midgut NET
biomarker for diagnosis and monitoring treatment response (Mamikunian et al., 2011;
Vinik & Gonzales, 2011). Pancreastatin also correlates with liver metastases (A. Vinik et
al., 2009). In a study of NET patients who had hepatic artery chemoembolization,
extremely elevated plasma pancreastatin levels (greater than 5000 pg/mL) were
connected to higher rates of periprocedural mortality (A. Vinik et al., 2009; Vinik et al.,
2011). As a novel biomarker of NETs, further studies on pancreastatin are warranted.
Serotonin. Serotonin can be a marker for NETs in the bronchus and ileum with
intermediate specificity (Modlin et al., 2008). Foregut NETs produce more serotonin than
midgut NETs (A. Vinik et al., 2009). Less commonly, serotonin has been measured in
serum to monitor the functionality and growth of well-differentiated midgut NETs
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(Diebold et al., 2012). Of note, patients with pancreatic NETs generally do not secrete
serotonin, but a small percentage of these tumors do (Kawamoto et al., 2011l Kulke et al.,
2011). In a small review of clinical cases, Kawamoto et al. (2011) discussed serotoninproducing pancreatic NETs causing pancreatic duct obstruction and fibrosis. Serotonin is
also one of the biomarkers for flushing associated with foregut and midgut tumors (A.
Vinik et al., 2009; Vinik & Gonzales, 2011). In animal and human studies, serotonin was
associated with carcinoid heart disease—it may have a role in its pathogenesis (Dobson et
al., 2013; A. Vinik et al., 2009). More studies related to serotonin as a marker are
necessary to clarify its role in NETs.
5-hydroxyindoleacetic acid. Urinary 5-HIAA is a longstanding biomarker for
NETs (Eriksson et al., 2000). It can be measured as a surrogate marker for serotonin
because it is a breakdown product of the latter, and it has a reported specificity of 88%
(Modlin et al., 2008; Vinik & Gonzales, 2011). An historic study with a larger patient
population (N = 290) reported 5-HIAA’s specificity and sensitivity at 100% and 35%,
respectively (Seregni et al., 2001). Kulke et al. (2011) and Diebold et al. (2012) noted
that urinary 5-HIAA is a useful diagnostic marker for patients who have metastatic
carcinoid tumors in the midgut. In their study, Van der Horst-Schrivers et al. (2007)
determined that urinary 5-HIAA functions as an independent prognostic marker that can
be used during patients’ initial and follow-up visits. It can be used to assess tumor
progression and functionality in midgut NETs as well (Diebold et al., 2012). Of note, 5HIAA is also a biomarker for NETs in the bronchus and ileum at intermediate and high
specificity, respectively (Modlin et al., 2008). 5-HIAA is also one of the biomarkers for
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NET-related flushing and has been linked to carcinoid heart disease progression (Dobson
et al., 2013; A. Vinik et al., 2009). High urinary levels of 5-HIAA are associated with
lower survival rates as well (Van der Horst-Schrivers et al., 2007).
Despite its usefulness as a NETs marker, 5-HIAA can have problematic false
positives, and certain medications or foods can increase urinary 5-HIAA levels
(Mamikunian et al., 2011; Vinik & Gonzales, 2011). Due to the issues related to false
positives, it is recommended that 5-HIAA is measured via a 24-hour urine collection
(Tellez, Mamikunian, O'Dorisio, Vinik, & Woltering, 2013). Tellez et al. (2013)
compared 5-HIAA values from a 24-hour urinary collection with plasma 5-HIAA values
in a group of 115 patients. The resulting correlations from the regression analysis were
statistically significant, indicating that plasma and urinary 5-HIAA levels from the same
patient are similar (Tellez et al., 2013). Plasma 5-HIAA measures could be a viable
alternative to urinary 5-HIAA measures (Tellez et al., 2013). In another study, Dobson et
al. (2013) found that plasma 5-HIAA had significant discriminatory value for carcinoid
heart disease diagnosis in a population of 187 NET patients. Additional research about
the relationship between 5-HIAA and NETs is still needed.
Neuroendocrine Tumors and Quality of Life
Arthur Pigou defined QOL in 1920—the WHO revisited the concept and
incorporated health in its definition in 1948 (CDC, 2011; Ormel et al., 1997; Vinik et al.,
2011; Vinik et al., 2014). QOL is a complex, multidimensional concept comprised of
patients’ experiences, their well-being, and how their illness affects their lives (CDC,
2011; E. Vinik et al., 2009). It is an indicator for health outcomes, responds to clinical
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changes, and can be used to predict morbidity/mortality as well (CDC, 2011; Ormel et al.,
1997; Vinik et al., 2011; Vinik et al., 2014).
In their explanatory model, Ormel et al. (1997) illustrated how a disease (or
disorder) results in physical and mental impairments, leading to symptoms and functional
limitations—these things ultimately impact an individual’s QOL. As noted in other
studies, QOL is the dependent variable that changes based on the domains (independent
variables) in the tool (e.g., physical functioning, positive/negative attitude, and so forth;
Stuifbergen et al., 2000). The individual domains in an instrument can measure the
physical, social, and emotional aspects that contribute to overall health-related QOL.
Tools that measure QOL “…make it possible to demonstrate scientifically the impact of
health on quality of life, going well beyond the old paradigm that was limited to what can
be seen under a microscope” (CDC, 2011, para. 6).
Over the last decade, a greater interest has arisen in patient-reported QOL, and it
has become an endpoint for clinical trials (E. Vinik et al., 2009; Vinik et al., 2011). Since
the 1970s, instruments to measure health-related QOL have transitioned from generic to
disease-specific (Vinik et al., 2011; Vinik et al., 2014). The United States Food and Drug
Administration requires that clinical trials for new therapies measure QOL/patientreported outcomes because this information can help researchers determine whether the
disease or intervention is affecting the participants (Vinik et al., 2011; Vinik et al., 2014).
QOL can help physicians better understand the effects of a chronic illness (such as NETs)
on a patient as well as the relationship between risk factors (e.g., behaviors) and a disease
(CDC, 2011; Ormel et al., 1997; E. Vinik et al., 2009; Vinik et al., 2011). Davis (2009)
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pointed out that QOL is one of the most critical measurable outcomes for cancer patients.
It is possible that some treatments may improve QOL, while others (like chemotherapy or
radiation) can adversely affect it (Davis, 2009; Vinik et al., 2011; Vinik et al., 2014).
Historically, Larsson, von Essen, and Sjödén’s (1998) QOL study in patients with
gastrointestinal NETs showed a need for enhanced communication between hospital staff
and patients. Researchers indicated that NET patients have diminished QOL when
compared to a general population as well (Fröjd et al., 2007; Haugland et al., 2013;
Larsson et al., 2001; E. Vinik et al., 2009; Vinik et al., 2011; Vinik et al., 2014;
Yadegarfar et al., 2013). Consequently, there is not a vast body of literature regarding
QOL and NETs (Yadegarfar et al., 2013). This remains an understudied area in the field,
which provides this study the opportunity to make a contribution to existing knowledge
about QOL and NETs.
NET-Specific QOL Instruments
In 2004, one of the first health-related QOL tools for NETs was developed and
later validated, the Norfolk QOL-NET (E. Vinik et al., 2009; Vinik et al., 2014). The
Norfolk QOL-NET is a 72-item instrument that “…captures 11 symptoms and it
measures both frequency and severity of symptoms” (Vinik et al., 2011, p. 100). The
Norfolk QOL-NET has seven domains, including physical functioning, respiratory,
depression, cardiovascular, gastrointestinal, flushing, and positive/negative attitude (E.
Vinik et al., 2009). Of these domains, physical functioning contributes the most (40% or
26/65 items) to overall QOL score (E. Vinik et al., 2009). The Norfolk QOL-NET is
described in greater detail in Chapter 3.
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The EORTC QLQ-C30 QLQ-GINET-21 is another clinically sensitive, validated
NET-specific QOL tool (Yadegarfar et al., 2013). The EORTC QLQ-C30 by itself is a
validated, 30-item questionnaire that measures “generic aspects of cancer” (Davies et al.,
2006; Vinik et al., 2011, p. 99; Yadegarfar et al., 2013). Responses are given based on a
4-point Likert scale (Yadegarfar et al., 2013). In an effort to capture disease specific
information, modules are attached to the QLQ-C30. The QLQ-C30 QLQ-GINET-21
includes a 21-question, NET-specific module (with three multi-symptom scales) with the
standard QLQ-C30 tool that was developed by the EORTC QOL group (Davies et al.,
2006; Yadegarfar et al., 2013). This is in contrast to the Norfolk QOL-NET, “…an allinclusive single tool for measuring the subjective, self-reported effects of NETs on QOL”
(E. Vinik et al., 2009, p. e94). The QLQ-GINET21 itself is responsive for the
measurement of NETs in the gut, liver, and pancreas (Yadegarfar et al., 2013). The
Norfolk QOL-NET measures symptom severity and frequency for eleven symptoms over
a 4-week period (E. Vinik et al., 2009; Vinik et al., 2011). The eleven symptoms include
the following: flushing; joint/bone pain; other pain; peripheral edema; wheezing; diarrhea
or constipation; rash; cyanosis; telangiectasia; fatigue; and coughing (E. Vinik et al.,
2009). In comparison, the EORTC QLQ-C30 QLQ-GINET-21 asks about a single-week
timeframe (except for the question about sexual activity), and they do not inquire about
the same systems (E. Vinik et al., 2009; Vinik et al., 2011).
NETs and QOL Studies
As mentioned previously, there is not a vast body of literature about QOL and
NETs. Some studies used generic tools to capture QOL in NET patients, while others
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used the European or Norfolk QOL-NET instruments. These studies are discussed in the
following section.
Fröjd et al. (2007) used the EORTC QLQ-C30 to evaluate QOL and psychosocial
function in a Swedish population of NET patients. Participants’ levels of anxiety and
depression were measured using the Hospital Anxiety and Depression Scale (HADS;
Fröjd et al., 2007). Fröjd et al. (2007) created an instrument with a 4-week timescale for
three major dimensions of aspects of distress: social restrictions (5 aspects); emotional (9
aspects); and physical (10 aspects). Each aspect was scored via a 5-point Likert scale
(Fröjd et al., 2007). To create this instrument, the investigators used data from semistructured interview questions given to patients and nurses in a previous study (Fröjd et
al., 2007). Patient data from the three instruments were compared with data from the
Swedish general population (Fröjd et al., 2007). An ANOVA and one-sample t-tests were
used to analyze data. Interestingly, the investigators discovered that QOL and
psychosocial function were stable during patients’ first year post-diagnosis (no significant
differences); however, after that time period, NET patients’ QOL (particularly emotional
distress) was lower than that of the general population (Fröjd et al., 2007). At all
assessments, patients had higher levels of cognitive, emotional, physical, and social
function than overall QOL and role function (p<0.01; Fröjd et al., 2007). Compared
against the general population, patients had increased issues with diarrhea and fatigue as
well as lower overall QOL and role function scores (Fröjd et al., 2007). Patients had
increased worries about caring for their family, their family’s situation, and medical
check-ups at all assessment points too (Fröjd et al., 2007). Physicians and researchers
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could use these results to implement methods or interventions that would reduce the
distress/worry for their NET patients.
In a cross-sectional study, Haugland, Vatn, Veenstra, Wahl, and Natvig (2009)
compared QOL data for 196 NET patients and 5,258 members of the general Norwegian
population. QOL was measured with the standard SF-36 instrument. ANOVA and t-tests
were used to analyze the QOL data (Haugland et al., 2009). As anticipated, NET patients
had significantly lower QOL scores than the general population (Haugland et al., 2009).
In particular, the vitality, general health, and physical limitation scales had the lowest
scores (Haugland et al., 2009). Investigators found that elderly individuals (older than 70
years of age) had lower physical functioning and physical limitation scores, which
conflicted with previous studies that did not have a significant difference between QOL
and age (Haugland et al., 2009). Individuals who were retired also had lower scores in
these categories than individuals who were working (Haugland et al., 2009). Education
appeared to be a factor as well—participants with higher education levels had better
physical functioning scores than participants with less education (Haugland et al., 2009).
Haugland et al. (2013) looked for changes in QOL, stress, and self-efficacy in 37
NET patients who participated in a multidisciplinary educational intervention based on
self-efficacy principles. The intervention provided patients with problem-solving
strategies to manage and live with NETs. The investigators used the well-established,
generic SF-36 tool for QOL, a modified version of the Impact of Event Scale for stress,
and the General Self-Efficacy Scale for self-efficacy (Haugland et al., 2013). After the
intervention, participants showed significant improvements in stress, self-efficacy, and
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the physical component of QOL (Haugland et al., 2013). Men had a significantly
increased change in the physical component of QOL when compared to female
participants as well (Haugland et al., 2013).
Knox et al. (2004) assessed survival and longitudinal functional QOL in patients
who had undergone resection for hepatic carcinoid metastasis (HCM). Patients with
HCM have a poor prognosis (5-year survival rate of 20%-30%) and carcinoid syndrome
(Knox et al., 2004). The investigators measured functional QOL (via Karnofsky
functional scores), three biomarkers (CgA, NSE, and 5-HIAA), and survival as their main
outcome measures (Knox et al., 2004). Knox et al. (2004) observed a significant
improvement in functional QOL after the surgical resection in addition to tumor marker
normalization and prolonged survival. Of note, there was a significant association
between resection of greater than or equal to 90% tumor volume and normalization of the
tumor markers as well as survival (Knox et al., 2004).
There have been some studies that compared QOL to NET biomarkers (Korse et
al., 2009; Larsson et al., 2001; Vinik et al., 2011; Vinik et al., 2014). Over a decade ago,
Larsson et al. (2001) used the EORTC QLQ-C30 and HADS to evaluate QOL and
anxiety/depression, respectively, in patients with midgut NETs during their first year of
treatment. Patients’ functional ability was measured via the Karnofsky Performance
Status Scale (Larsson et al., 2001). Patient data were compared against data from the
general Swedish population as well (Larsson et al., 2001). These three instruments were
administered at baseline and an additional four times across a 12-month period (Larsson
et al., 2001). Investigators also obtained participants’ plasma CgA and urinary 5-HIAA at
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each time point as well (Larsson et al., 2001). One-sample t-tests were used to analyze
the data from the instruments, and Pearson’s correlations were done between the
instrument scores and biomarkers. Larsson et al. (2001) did not find a relationship
between the biomarkers and QOL; furthermore, tumor marker levels did not correlate
with psychosocial function. However, there were significant correlations between CgA
and 5-HIAA with diarrhea at the 12-month point (Larsson et al., 2001). They did observe
significant improvement in symptoms in patients, including anxiety, flushing, and
nausea/vomiting (Larsson et al., 2001). Patients had increased muscle pain and decreased
physical functioning over the year as well (Larsson et al., 2001). When compared to the
general population, patients had lower overall QOL too (Larsson et al., 2001).
Interestingly, the authors of this study cited a need for a NET-specific assessment tool in
their conclusion (Larsson et al., 2001).
Korse et al. (2009) compared urinary 5-HIAA and CgA “…as part of the
evaluation of the response to treatment with a somatostatin analog” in a European patient
population (p. 297). Response to treatment was evaluated using the EORTC QLQ-C30
with the carcinoid-specific symptom scale, QLQ-GINET21 (Korse et al., 2009). Korse et
al. (2009) specifically focused on diarrhea, physical functioning, and overall QOL. Mixed
linear models were used to evaluate the QOL and tumor marker outcomes, while Cox
regression analysis was used to assess survival (Korse et al., 2009). CgA correlated
significantly with overall QOL and physical functioning, whereas 5-HIAA did not
correlate with either of them (Korse et al., 2009). There was also a significant association
between survival time and CgA levels, but not between survival time and 5-HIAA (Korse
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et al., 2009). Korse et al. (2009) stated that their findings implied that CgA is a better
biomarker for NET patients than 5-HIAA.
Vinik et al. (2011) conducted a study where 29 patients filled out both the Norfolk
QOL-NET and the EORTC QLQ-C30 QLQ-GINET-21. Results from the questionnaires
were also compared against biomarkers (Vinik et al., 2011). Spearman’s nonparametric
correlations were used to obtain correlation data between the questionnaires and
biomarkers; additionally, regression analysis was employed to discern whether or not
results from the two questionnaires correlated with each other (Vinik et al., 2011). With
the exception of the cardiovascular domain, the QOL scores from the two questionnaires
correlated positively; notably, the EORTC QLQ-C30 QLQ-GINET-21 does not have
cardiovascular-related questions (Vinik et al., 2011). The Norfolk QOL-NET’s physical
functioning domain had the strongest correlation with the total score of both
questionnaires (Vinik et al., 2011). Correlation between the two questionnaires indicated
that they are both effective in the clinic (Vinik et al., 2011). Serotonin had a significant,
positive correlation with total QOL from both questionnaires as well (Vinik et al., 2011).
Additional research related to this study found correlations between tumor burden and
three of the Norfolk QOL-NET’s domains: physical functioning, depression, and
gastrointestinal (Vinik et al., 2014). A significant correlation between the biomarker
serotonin, total QOL from the Norfolk QOL-NET, total QOL from the EORTC QLQC30 QLQ-GINET-21, and the three domains (physical functioning, depression, and
gastrointestinal) was observed as well (Vinik et al., 2014). It was noted that the Norfolk
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QOL-NET has more questions in their respiratory and flushing domains than the EORTC
QLQ-C30 QLQ-GINET-21 as well (Vinik et al., 2014).
Summary
NETs, originating from neuroendocrine cells, are a rare, complicated collection of
neoplasms that are difficult to diagnose. Clinical pathogenesis and presentation are
influenced by the amines and hormones produced by these tumors, which is why it is
critical to continue researching how these biomarkers and primary tumor sites affect
NETs. While there is a more known about some biomarkers of the disease (such as CgA,
serotonin, and 5-HIAA) than others, the literature demonstrated that additional studies are
warranted. There is less information available about gastrin, NKA, and pancreastatin’s
roles in NETs, which indicates a need for more studies about these novel biomarkers.
As a challenging chronic illness, NETs also affect patients’ QOL. In particular,
NETs can lessen patients’ physical functioning and total QOL. Although there is a greater
interest in patient-reported outcomes and NET research, there is not a vast body of
literature related to QOL and NETs. There is a need for further studies that provide a
deeper understanding of the relationship between NETs and QOL. Given what is known
about the impact made by disease biomarkers and NETs with different origin sites on the
various aspects of the disease, it is feasible to hypothesize that the tumor of origin and/or
biomarkers expressed by those tumors could affect NET patients’ QOL. The present
study moved beyond previous studies to determine whether there was a relationship
between the total QOL of patients with different primary tumor sites. The relationship
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between total QOL and disease-specific biomarkers was also assessed. The methodology
used to address this gap in knowledge is explained further in Chapter 3.
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Chapter 3: Research Method
Introduction
The purpose of this study was to examine the relationship between total QOL and
patients’ primary tumor sites in addition to investigating the relationship between total
QOL and six novel biomarkers of NETs. This chapter discusses the study’s design and
approach. It also includes a description of the secondary database from the
Neuroendocrine Unit at Eastern Virginia Medical School in Norfolk, Virginia, henceforth
referred to as the QOL-NET database. The Norfolk QOL-NET instrument is described
along with the study’s analytical approach and ethical considerations as well.
Research Design and Rationale
I took a quantitative approach to analyzing the secondary, de-identified clinical
data that were collected using the Norfolk QOL-NET instrument to evaluate the
relationships between these variables. Furthermore, the data were quantitative, crosssectional, and only generalizable to the NET patient population in the same age range as
the patients in the dataset. A quantitative approach aligned with the analysis of
questionnaire-based numerical data and the study’s purpose to advance knowledge in the
discipline. The total QOL score was the dependent variable. The biomarkers and primary
tumor sites were evaluated as independent variables to determine whether they affected
patients’ total QOL. There were no time or resource constraints associated with this
research.
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Methodology
Population
For this study, I used data from 134 female and male patients diagnosed with
NETs. The age range for these patients was 18-85 years of age.
Recruitment, Participation, and Data Collection
Data in the QOL-NET database were collected from patients with a diagnosed
NET who were asked to participate in a study during clinic visits (Vinik et al., 2011; A.
Vinik & E. Vinik, personal communication, July 1, 2015). Patients signed informed
consent forms to participate and have their de-identified data used in research (Vinik et
al., 2011; A. Vinik & E. Vinik, personal communication, July 1, 2015). Patients who did
not have a NET were not asked to participate. I did not have any information about how
the patients in the clinic were different from other patients, nor did I have information
about whether they were referred there, which may be considered a limitation. It was also
unknown how the patients who agreed to participate were different from those who did
not.
The QOL-NET database was in an Excel file that contained information for 134
NET patients. Dr. Aaron Vinik (Professor, Eastern Virginia Medical School
Neuroendocrine Unit) provided the QOL-NET database and gave permission for it to be
used in this study (Appendix A). All of the data were already de-identified, and patients
were listed by a numerical Patient ID in the database.
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Sample and Sampling Procedures
The patient sample for the QOL-NET database was obtained in the clinic, as
patients with a NET were asked to take part in the survey (Vinik et al., 2011; A. Vinik &
E. Vinik, personal communication, July 1, 2015). There were data available from 134
individuals in this single database. For this study, sample size was determined using the
online calculator from Raosoft (Raosoft Inc., 2004). This online calculator takes margin
of error, confidence level, population size, and response distribution into account when
determining a minimum recommended sample size (Raosoft Inc., 2004). A standard
margin of error (5%) was selected along with a standard confidence level of 95% (α =
.05). The population size was given as 134, the number of individuals in the database.
The response distribution was entered as 50%. Per Raosoft, Inc. (2004), when the
response distribution to questions is unknown, using 50% is appropriate because it will
yield a larger sample size. For this study, the recommended sample size from the Raosoft
calculator was 100 individuals. Consequently, data from all 134 patients were analyzed
because they were available, and using all of the data in the single dataset avoided having
to make any type of limiting selection that could have introduced sampling bias into the
study.
Instrumentation and Operationalization of Constructs
The Norfolk QOL-NET is a 72-item, disease-specific instrument designed in 2004
to fill a gap in neuroendocrine tumor and carcinoid research literature (E. Vinik. et al.,
2009; Vinik et al., 2014). The development and validation of the Norfolk QOL-NET took
investigators three years to complete at Eastern Virginia Medical School in Norfolk,
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Virginia (E. Vinik et al., 2009). Questions were initially developed with a panel of
experts to ensure content validity, and the tool was later pilot tested with NET patients in
a focus group (E. Vinik et al., 2009). The experts and patients provided useful
suggestions that facilitated the refinement of the instrument (E. Vinik et al., 2009).
The instrument includes a cover page that asks patients about their history with
NETs, common NET symptoms, and demographic information. The Norfolk QOL-NET
is scored on a 5-point Likert scale (E. Vinik et al., 2009). It was designed to capture
symptom severity and frequency along with activities of daily living, somatostatin
injections, and a feelings scale (E. Vinik et al., 2009). A copy of the tool is presented in
Appendix B. The instructions in the first three sections of the tool ask the patients to rate
these items over the last 4 weeks. The instructions for the final part of the tool, the
feelings scale, asks patients to describe how often they felt or behaved a certain way over
the last seven days (E. Vinik et al., 2009). Items 1-11 (Part 1a) measure the frequency of
NETs-related symptoms and is scored on a range of “no symptoms” to “more than once a
day” (E. Vinik et al., 2009). Items 12-22 (Part 1b) measure the severity of NETs-related
symptoms, ranging from “no symptoms” to “extremely severe” (E. Vinik. et al., 2009).
The remaining items in the questionnaire are as follows: items 23-54 (Part 2) measure
activities of daily living; items 55-58 (Part 3) measure how patients feel about their
somatostatin/sandostatin injection; and items 59-72 (Part 4) comprise the “Feelings
Scale” (E. Vinik et al., 2009).
Psychometric factor analysis was performed on the instrument’s items to ascertain
the number of domains within it (E. Vinik et al., 2009). Ultimately, the psychometric
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analysis identified seven domains in the Norfolk QOL-NET: cardiovascular, depression,
flushing, gastrointestinal, physical functioning, positive/negative attitude (referred to as
“attitude” henceforth), and respiratory (E. Vinik et al., 2009; Vinik et al., 2014).
A Cronbach’s α test was used to assess internal consistency of the items in the
questionnaire, and discriminatory capability was assessed via a case-control study
performed at the Neuroendocrine Unit (E. Vinik et al., 2009). Results from the
Cronbach’s α for each domain was 0.86 or higher, indicating a high level of internal
consistency within each of the scales (E. Vinik et al., 2009). The results from the casecontrol study showed that the total QOL score was capable of discriminating between a
NET population and a healthy population, but the scores for the specific domains were
not significant discriminators, indicating that the NET patients have symptoms that are
common in healthy individuals (E. Vinik et al., 2009, p. e93). This finding highlights part
of the challenge of diagnosing NET patients—healthy individuals may also experience
fatigue, abdominal pain, coughing, irritable bowel syndrome, and other similar symptoms
that are common for NET patients (E. Vinik et al., 2009). The case-control study also
showed that physical functioning, depression, flushing, and gastrointestinal domains were
all significantly higher for NET patients, whereas the cardiovascular, respiratory, and
attitude domains were not significant (E. Vinik et al., 2009). Investigators evaluated the
instrument’s reliability in the same cohort of patients via a test-retest analysis, and the
results showed that there were no significant differences between the first questionnaire
and the second questionnaire, demonstrating good reliability. (E. Vinik et al., 2009).
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Operationalization
The database contained the following data: basic demographic data on age,
gender, and race; patients’ yes/no responses to the Norfolk QOL-NET cover page
(Appendix B); their numerical responses to the 72-item questionnaire; total QOL scores
for all patients; numerical values for pancreastatin, NKA, serotonin, 5-HIAA, CgA, and
gastrin; whether the biomarker values are normal (nominal data: yes, no, no-low); and the
primary tumor site (nominal data). For all patients, age was a numerical value. Gender
and race were both categorical variables. The following questions from the cover page of
the Norfolk QOL-NET had dichotomous responses (yes or no): have you been told you
have or had a carcinoid tumor; do you have a family history of neuroendocrine tumors;
do you have an endocrine tumor; do you have an endocrine tumor; in the past month,
have you lost weight without trying; do you have a history of high blood pressure; do you
have any carcinoid syndromes; do you have flushing; is the flushing hot; and do you
sweat when you flush.
Questions 1-72 of the Norfolk QOL-NET are scored numerically. All of the
questions and scales are in the copy of the instrument located in Appendix B. Questions
1-11 (Part Ia: Symptom Frequency), Questions 12-22 (Part Ib: Symptom Severity),
Questions 23-53 (Part II: Activities of Daily Life), and Questions 59-72 (Part IV:
Feelings Scale) of the Norfolk QOL-NET are scored on a 5-point Likert scale. Question
54 (Part II) is scored on a 6-point Likert scale. Questions 55-58 (Part III: Somatostatin
Injection Scale”) are not part of the total QOL score, but they are scored on a 5-point
Likert scale.

56
Numerical data for total QOL and the total scores for the seven domains
(depression, flushing, respiratory, gastrointestinal, cardiovascular, physical functioning,
and attitude) were in the database as well. The biomarker data for pancreastatin, NKA,
serotonin, 5-HIAA, CGA, and gastrin were also in the database. These were continuous,
interval data. Additionally, the database contained dichotomous variables (yes/no) called
Pancreastatin Normal, NKA Normal, Serotonin Normal, CGA Normal, and Gastrin
Normal.
Data Analysis Plan
Descriptive statistical analyses were conducted on the following patient data from
the dataset: data from the first page of the QOL-NET about patients’ history with NETs,
common NET symptoms, and demographic information; all 72 questions in the QOLNET; total QOL score; scores for the seven domains; and biomarker data. The data from
NET patients were analyzed using SPSS version 23 to answer two research questions:
Research Question 1: What is the relationship between the primary tumor site and
NET patients’ total QOL score?
H01: There is no relationship between the primary tumor site and NET patients’
total QOL score.
H11: There is a relationship between the primary tumor site and NET patients’
total QOL score.
Research Question 2: How does the presence of specific NET biomarkers (NKA,
pancreastatin, serotonin, 5-HIAA, gastrin, and CgA) affect the total QOL score for
NET patients?
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H02: The presence of specific NET biomarkers (NKA, pancreastatin, serotonin, 5HIAA, gastrin, and CgA) does not affect the total QOL score for NET patients.
H12: The presence of specific NET biomarkers (NKA, pancreastatin, serotonin, 5HIAA, gastrin, and CgA) affects the total QOL score for NET patients.
For Research Question 1, primary tumor site was treated as the independent
variable, and total QOL score was the dependent variable. It was hypothesized that there
was a relationship between the primary tumor site and total QOL. With a categorical
independent variable and a continuous dependent variable, a one-way ANOVA test was
used to assess the relationship between primary tumor site and total QOL score. A oneway ANOVA looked for differences among the means of the primary tumor sites, and it
was followed by a post hoc test (e.g., a Tukey HSD test) to determine where the
differences were in this patient population. Any results with a p-value less than 0.05 were
considered significant and supportive of the hypothesis that there was a relationship
between the primary tumor site and total QOL score.
Related, separate one-way ANOVAs were also used to determine whether there
was a relationship between the following: total QOL (dependent variable) and age groups
(independent variable; 18-29 years; 30-39 years; 40-49 years; 50-59 years; 60-69 years;
and 70-85 years); total QOL and gender (independent variable; male and female); and
total QOL and race (independent variable). A post hoc test was also conducted for these
analyses. A multiple linear regression analysis was conducted to determine whether
multiple independent variables (age, gender, race, and primary tumor site) affected total
QOL.
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For Research Question 2, the presence of NET biomarkers (categorical variable)
was treated as the independent variable, and total QOL score (continuous variable) was
the dependent variable. It was hypothesized that specific NET biomarkers affected the
total QOL score for NET patients. A one-way ANOVA was also used in this analysis,
followed by a post hoc test. Any results with a p-value less than 0.05 was considered
significant and supportive of the hypothesis that there was a relationship between the
NET biomarkers and total QOL score. A multiple linear regression analysis was also
conducted to determine whether multiple independent variables (age, gender, race, and
biomarker presence) affected total QOL.
Threats to Validity
Self-reported data can be limiting and introduce potential bias to a study, which
threatens internal validity. Studies that use self-reported data can be affected by recall
bias, as patients may not clearly remember the information asked by the survey questions.
Reporting bias could also threaten the study’s internal validity because patients may have
not answered questions accurately for whatever reason. Selection bias was another
potential threat to validity because the patients in the QOL-NET database were selected
based on having a NET.
One of this study’s assumptions was that patients responded to the Norfolk QOLNET honestly. It was assumed that the biomarker measures were clinically valid as well.
The fact that researchers previously validated the Norfolk QOL-NET and established its
reliability reduced some threats to the study’s internal validity (E. Vinik et al., 2009). It
was assumed that what was measured by the instrument is representative of NET
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patients’ QOL. Data were not generalized to any population other than a NET patient
population in the same age range to reduce any threat to external validity. The differences
in the interpretation between age groups may be a limitation and are discussed further in
Chapter 5. An erroneous conclusion about the associations between variables in the study
could have threatened statistical conclusion validity. A reliable instrument and an
adequately powered study reduced this type of threat to validity.
Ethical Procedures
Prior to initiating the study, Institutional Review Board (IRB) approval was
obtained from the Walden University IRB (IRB approval number: 03-29-16-0245646).
Since archival data were being used, there were no ethical concerns related to recruitment
or data collection. Dr. Vinik of Eastern Virginia Medical School granted permission to
use the QOL-NET database for the purpose of this study (Appendix A). Data in the QOLNET database were already de-identified; thus, there was no information that could have
been used to identify any of the patients who filled out the Norfolk QOL-NET
instrument. The de-identified data came from patients who provided consent. The
database is stored on my personal computer, and I am the only one with access to it. It
will remain confidential and be password-protected to ensure that it is secure. The QOLNET database will be maintained securely for five years, at which point it will be
destroyed.
Summary
Secondary QOL, primary tumor site, and biomarker data from 134 NET patients
were evaluated to answer two research questions. The first question assessed the
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relationship between primary tumor site and total QOL score. The second question
examined whether specific NET biomarkers affected total QOL score. The results from
these analyses and whether they answered the two research questions are discussed in
Chapter 4.
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Chapter 4: Results
Introduction
The purpose of this quantitative study was to examine the relationship between
total QOL and patients’ primary tumor sites in addition to investigating the relationship
between total QOL and six novel biomarkers of NETs (5-HIAA, CgA, gastrin, NKA,
pancreastatin, and serotonin). The research questions and hypotheses for this study are as
follows:
Research Question 1: What is the relationship between the primary tumor site and
NET patients’ total QOL score?
H01: There is no relationship between the primary tumor site and NET patients’
total QOL score.
H11: There is a relationship between the primary tumor site and NET patients’
total QOL score.
Research Question 2: How does the presence of specific NET biomarkers (NKA,
pancreastatin, serotonin, 5-HIAA, gastrin, and CgA) affect the total QOL score for
NET patients?
H02: The presence of specific NET biomarkers (NKA, pancreastatin, serotonin, 5HIAA, gastrin, and CgA) does not affect the total QOL score for NET patients.
H12: The presence of specific NET biomarkers (NKA, pancreastatin, serotonin, 5HIAA, gastrin, and CgA) affects the total QOL score for NET patients.
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The secondary dataset and the results from the data analyses of the NET patients’
data in the QOL-NET dataset are discussed in this chapter. The findings from those
analyses are also summarized.
Data Collection
Secondary, de-identified clinical data (collected in 2011-2012 using the Norfolk
QOL-NET instrument) were evaluated in this study. The dataset contained QOL, primary
tumor site, and biomarker data for 134 female and male patients diagnosed with NETs.
Prior to starting the analyses, the Excel dataset was searched for any anomalies and
missing data. Throughout the dataset, missing data were assigned a missing data code,
99. For the analyses, 99 was entered as a discrete missing value for each variable in SPSS
version 23. In the demographics data, there were also instances where “N/A” was entered
into a field. These instances were also assigned a second missing data code, 98. (For the
demographic variables, both 98 and 99 were entered as discrete missing values in SPSS.)
Under the Primary Tumor Site variable, an undefined acronym was found, “TI.”
Per a personal communication with Dr. Vinik, the owner of the QOL-NET database, “TI”
represents small intestine carcinoids associated with appendix tumors, and it is
appropriate to refer to them as “appendix/small bowel” in the dataset (A. Vinik & E.
Vinik, personal communication, May 13, 2016). As such, all instances of “TI” were
changed to “appendix/small bowel” under this variable. Further examination of the
Primary Tumor Site variable showed that some patients had an unknown primary tumor
site, which is not unexpected with NETs (Keiser, Bergsland, & Nakakura, 2012). There
were four other patients who had a primary tumor site unlike the rest of the patients
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(kidney, cecum, TI + pancreas, and pheochromocytoma). Since having a single data point
in each of these additional primary tumor site categories would complicate the analyses,
they were grouped together as “Other.” Only one patient had jejunum listed as the
primary tumor site. Since the jejunum is part of the small intestine, that patient was
included in the “Small Bowel” group. Given the large number of primary tumor sites,
there was concern that they would affect the reliability of the analyses for Research
Question 1. As such, the primary tumor sites were condensed into their larger organ
groups when possible. A variable was created for this purpose called Primary Tumor Site
Condensed. Colon, rectal, and appendix were combined into a “Large Bowel” group.
Cecum was moved out of “Other” to the “Large Bowel” group as well. Duodenum and
ileum were added to the “Small Bowel” group.
There were also other variables created for analyses purposes. For the one-way
ANOVA and regression analyses, an Age Groups variable was created that assigned
patients to one of six groups based on their age: 18-29 years, 30-39 years, 40-49 years,
50-59 years, 60-69 years, and 70-85 years. All of the biomarkers except 5-HIAA had
categorical variables (yes/no), [Biomarker Name] Normal. As such, a 5-HIAA Normal
variable was created based on the normal range provided by Dr. Vinik (A. Vinik,
personal communication, May 13, 2016). Since there was little diversity in the Race
variable, a new variable (Race2) was created where the “W/NA” (White/Native
American) and “H” (Hispanic) categories were grouped together under “Other,” giving
the variable three levels: “White,” “Black,” and “Other.” Based on the information from
the six [Biomarker] Normal variables, I created a variable called Presence of Abnormal
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Biomarkers to account for patients having none, one, or multiple abnormal biomarker
measurements. This variable was coded as follows: 0-no abnormal biomarker measures;
1-abormal pancreastatin measurement only; 2-abnormal NKA measurement only; 3abnormal serotonin measurement only; 4-abnormal 5-HIAA measurement only; 5abnormal CgA measurement only; 6-abnormal gastrin measurement only; 7-2 abnormal
biomarker measurements; and 8-3 or more abnormal biomarker measurements. For this
variable, the 17 individuals with missing biomarker data were assigned the missing data
code, 99. Once the Excel file was imported into SPSS version 23, the scores for the total
QOL score and seven domain variables (depression, flushing, respiratory,
gastrointestinal, cardiovascular, physical functioning, and attitude) were rechecked as
well.
Results
Descriptive Statistics
There were a total of 134 patients in the QOL-NET dataset. Fifty-nine percent
(59%; n = 79) of the population was female, which is notable because NETs appear to be
more common in women than men in the United States (ACS, 2013). The average age of
the population was 57.77 years. Additional demographic data for age can be found in
Table 1. Data for race are in Table 2.
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Table 1
Demographic Data for the QOL-NET Dataset Patients—Age

18-29 Years Group
30-39 Years Group
40-49 Years Group
50-59 Years Group
60-69 Years Group
70-85 Years Group
Missing

Number of
Patients

Percent

3
7
24
37
42
17
4

2.2%
5.2%
17.9%
27.6%
31.3%
12.7%
3.0%

Table 2
Demographic Data for the QOL-NET Dataset Patients—Race

Race—White
Race—Black
Race—Hispanic
Race—White/Native
American
Missing

Number of
Patients

Percent

120
9
2
2

89.6%
6.7%
1.5%
1.5%

1

0.7%

Eighteen patients identified a family history of NETs. In the dataset, 129 patients
responded to the demographics question that asked whether they have NET-related
symptoms—65% of them responded “yes.” Total QOL scores ranged from a low of 5 to a
high of 230, with a mean score of 90.16. Appendix/small bowel and small bowel were the
most common primary tumor sites, as seen in Table 3. Thirty-one (23.7%) of the patients
had an unknown primary tumor site. For the purposes of the Research Question 1
analyses, primary tumor sites were grouped into larger organ systems, as noted above.
The frequencies of the condensed primary tumor sites are shown in Table 4.
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Table 3
Frequencies of Primary Tumor Sites in the QOL-NET Dataset

Appendix
Appendix/Small
Bowel
Colon
Duodenum
Gastric
Ileum
Lung
Other
Pancreas
Rectal
Small Bowel
Unknown
Total
Missing

Number of
Patients

Percent

7
21

5.3%
16.0%

5
10
7
5
9
4
12
5
15
31
131
3

3.8%
7.6%
5.3%
3.8%
6.9%
3.1%
9.2%
3.8%
11.5%
23.7%
100%

Table 4
Frequencies of Condensed Primary Tumor Sites in the QOL-NET Dataset

Appendix/Small Bowel
Gastric
Large Bowel
Lung
Other
Pancreas
Small Bowel
Unknown
Total
Missing

Number of
Patients

Percent

21
7
18
9
3
12
30
31
131
3

16.0%
5.3%
13.7%
6.9%
2.3%
9.2%
22.9%
23.7%
100%

Biomarker data were available for 117 patients. Ninety-two (92) patients had at
least one abnormal biomarker measurement. Of those 92 patients, 35 patients had one
abnormal biomarker measurement only (38.0%), 27 patients had two abnormal
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measurements (29.3%), and 30 patients had three or more abnormal biomarker
measurements (32.6%). Twenty-five (25) patients didn’t have any abnormal biomarker
measurements. In this population, abnormal NKA measurements were not observed
alone, but only in conjunction with other abnormal biomarker measurements. Table 5
shows the distribution of abnormal biomarker measurements in this population.
Table 5
Distribution of Abnormal Biomarker Measurements in the QOL-NET Dataset
No Abnormal Biomarker Measurement
Abnormal Pancreastatin Measurement Only
Abnormal Serotonin Measurement Only
Abnormal 5-HIAA Measurement Only
Abnormal CgA Measurement Only
Abnormal Gastrin Measurement Only
2 Abnormal Biomarker Measurements
3 or More Abnormal Measurements
Total
Missing

Number of Patients
25
5
8
3
17
2
27
30
117
17

Percent
21.4%
4.3%
6.8%
2.6%
14.5%
1.7%
23.1%
25.6%
100%

Table 6 shows whether or not individual biomarker measurements were normal
for patients in the dataset. It should be noted that not every patient will express the same
biomarkers, so missing data were expected.
Table 6
Whether or Not Biomarker Measurements are Normal in QOL-NET Patient Population
Pancreastatin
Normal
No
36 (41.4%)
Yes
51 (58.6%)
Total
87 (100%)
Missing 47

NKA
Normal
6 (10.7%)
50 (89.3%)
56 (100%)
78

Serotonin
Normal
45 (54.2%)
38 (45.8%)
83 (100%)
51

5-HIAA
Normal
22 (25.3%)
65 (74.7%)
87 (100%)
47

Research Question 1
Research Question 1 and its hypotheses are as follows:

CgA
Normal
65 (65.7%)
34 (34.3%)
99 (100%)
35

Gastrin
Normal
17 (53.1%)
15 (46.9%)
32 (100%)
102
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Research Question 1: What is the relationship between the primary tumor site and
NET patients’ total QOL score?
H01: There is no relationship between the primary tumor site and NET patients’
total QOL score.
H11: There is a relationship between the primary tumor site and NET patients’
total QOL score.
In Research Question 1, total QOL was the dependent variable and primary tumor
site was the independent variable. The condensed version of the primary tumor site
variable (referred to as “primary tumor site” henceforth), Primary Tumor Site Condensed,
was used for these analyses. A one-way ANOVA was conducted followed by a post hoc
test (Tukey HSD) to determine whether there were any significant differences in this
patient population. Any results with a p-value less than 0.05 was considered significant.
Separate one-way ANOVAs were conducted to determine whether there was a
relationship between the following: total QOL (dependent variable) and age groups
(independent variable; 18-29 years; 30-39 years; 40-49 years; 50-59 years; 60-69 years;
and 70-85 years); total QOL and gender (independent variable; male and female); and
total QOL and race (independent variable; white, black, and other). For these analyses, a
Tukey HSD post hoc test was conducted where appropriate. Additionally, a multiple
linear regression analysis was conducted to determine whether multiple independent
variables (age, gender, race, and primary tumor site) affected total QOL. All of the
independent variables were string variables and had to be recoded to run the multiple
linear regression analysis in SPSS.
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ANOVA results: Total QOL as the dependent variable. For a one-way
ANOVA, it was assumed that data were independent, had equal variances, and were
normally distributed. For the first ANOVA, total QOL (continuous) was the dependent
variable. Primary tumor site (categorical) was the independent variable. The condensed
version of the primary tumor site variable had eight categories: appendix/small bowel,
gastric, large bowel, lung, other, pancreas, small bowel, and unknown. There were three
missing data points in the primary tumor site variable. The ANOVA was not significant,
F (8, 125) = 0.834, p = 0.575. The η2 value indicated that primary tumor site only
accounted for approximately 5.1% of the variance of total QOL. This result supported the
null hypothesis that there is no relationship between primary tumor site and total QOL
score. This result is discussed further in Chapter 5.
None of the related, additional one-way ANOVAs conducted for Research
Question 1 were significant. Total QOL also served as the dependent variable for a oneway ANOVA where age groups were the independent variable. The age groups variable
had six levels: 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and 70-85
years (there were 4 missing data points). The result for this analysis was not significant
and can be seen in Table 7. The η2 value indicated that primary tumor site only
accounted for 1.9% of the variance of total QOL score.
Table 7
One-Way ANOVA Results for Comparison of Total QOL and Age Groups

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

7359.84
372337.76
1468984.48

6
127
134

1226.64
2931.79

0.418

0.866

0.019
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Total QOL was the dependent variable for a one-way ANOVA where gender was
the independent variable. Gender had two levels, female and male. The result for this
analysis was not significant, as shown in Table 8. The η2 value indicated that primary
tumor site only accounted for 2.3% of the variance of total QOL score.
Table 8
One-Way ANOVA Results for Comparison of Total QOL and Gender

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

8793.03
370904.57
1468984.48

1
132
134

8793.03
2809.88

3.129

0.079

0.023

In the final one-way ANOVA for Research Question 1, total QOL was the
dependent variable and race was the independent variable. Race had three levels: white,
black, and other. The result for this analysis was not significant, as seen in Table 9. The
η2 value indicated that primary tumor site only accounted for 1.1% of the variance of
total QOL score.
Table 9
One-Way ANOVA Results for Comparison of Total QOL and Race

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

4307.54
373790.97
1452084.48

2
130
133

2153.77
2875.32

0.749

0.475

0.011

Additional ANOVA results: QOL-NET domains as dependent variables.
Additional statistical tests related to this research question emerged during the analyses of
these data. Specifically, these tests were intended to determine whether any of the
individual domains of the QOL-NET (depression, flushing, respiratory, gastrointestinal,
cardiovascular, physical functioning, and attitude) were affected by primary tumor site.
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For each one-way ANOVA, one of the seven domains was treated as the dependent
variable, and primary tumor site was the independent variable. Post hoc tests (Tukey
HSD and Games-Howell) were conducted in SPSS to ascertain whether there were any
significant differences and to control for potential Type I error. Any results with a pvalue less than 0.05 were considered significant.
For the one-way ANOVA with the depression domain as the dependent variable
and primary tumor site as the independent variable, results were not significant, as shown
in Table 10. The η2 value indicated that primary tumor site only accounted for 7.3% of
the variance of the domain score. The result from the one-way ANOVA with the flushing
domain as the dependent variable and primary tumor site as the independent variable was
not significant as well, as shown in Table 11. For this analysis, the η2 value indicated that
primary tumor site only accounted for 3.9% of the variance of the domain score. The
result from the one-way ANOVA with the respiratory domain as the dependent variable
and primary tumor site as the independent variable was not significant (Table 12), and the
η2 value indicated that primary tumor site only accounted for 9.2% of the variance of the
domain score.
Table 10
One-Way ANOVA Results for Comparison of the Depression Domain and Primary
Tumor Site

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

991.81
12603.39
50873.00

8
125
134

123.978
2875.32

1.230

0.287

0.073
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Table 11
One-Way ANOVA Results for Comparison of the Flushing Domain and Primary Tumor
Site

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

225.21
5570.53
10348.68

8
125
134

28.15
44.56

0.632

0.750

0.039

Table 12
One-Way ANOVA Results for Comparison of the Respiratory Domain and Primary
Tumor Site

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

571.77
5669.72
10284.00

8
125
134

71.47
45.36

1.576

0.139

0.092

The one-way ANOVA for the next QOL-NET domain as the dependent variable
(gastrointestinal) and primary tumor site as the independent variable was not significant
(Table 13), and the η2 value indicated that primary tumor site only accounted for 4.0% of
the variance of domain score. Table 14 (below) shows that the result from the one-way
ANOVA with the cardiovascular domain as the dependent variable and primary tumor
site as the independent variable was not significant as well. The η2 value for this analysis
indicated that primary tumor site only accounted for 4.5% of the variance of domain
score. Table 15 (below) shows that the result from the one-way ANOVA with the
physical functioning domain as the dependent variable and primary tumor site as the
independent variable was not significant. The η2 value indicated that primary tumor site
only accounted for 6.3% of the variance of domain score. The final one-way ANOVA
treated the attitude domain as the dependent variable and primary tumor site as the
independent variable. Similar to the results of other one-way ANOVAs, this result was
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not significant (Table 16), and the η2 value indicated that primary tumor site only
accounted for 5.5% of the variance of domain score.
Table 13
One-Way ANOVA Results for Comparison of the Gastrointestinal Domain and Primary
Tumor Site

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

322.27
7808.12
21351.00

8
125
134

40.28
62.47

0.645

0.739

0.040

Table 14
One-Way ANOVA Results for Comparison of the Cardiovascular Domain and Primary
Tumor Site

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

140.34
2959.79
4702.64

8
125
134

17.54
23.68

0.741

0.655

0.045

Table 15
One-Way ANOVA Results for Comparison of the Physical Functioning Domain and
Primary Tumor Site

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

6548.32
96750.53
386207.63

8
125
134

818.54
774.00

1.058

0.397

0.063

Table 16
One-Way ANOVA Results for Comparison of the Attitude Domain and Primary Tumor
Site

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

55.03
938.51
2076.00

8
123
132

6.88
7.63

0.902

0.518

0.055
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Multiple linear regression analysis results. To conduct the multiple linear
regression analysis, it was assumed that the data were measured reliably, were normally
distributed, had equal variances, and that a linear relationship existed between the
independent and dependent variables. All of the independent variables were string
variables and had to be recoded to run the multiple linear regression analysis in SPSS. To
recode these variables, the “Automatic Recode” feature was applied to the appropriate
string variables in SPSS. Table 17 shows the recoded variables’ new values, as assigned
by SPSS.
Table 17
SPSS-Assigned New Values for Recoded String Variables
Original Value
Age: 18-29y
Age: 30-39y
Age: 40-49y
Age: 50-59y
Age: 60-69y
Age: 70-85y
Gender: Female
Gender: Male
Primary Tumor Site: Appendix/Small Bowel
Primary Tumor Site: Gastric
Primary Tumor Site: Large Bowel
Primary Tumor Site: Lung
Primary Tumor Site: Other
Primary Tumor Site: Pancreas
Primary Tumor Site: Small Bowel
Primary Tumor Site: Unknown
Race: White
Race: Black
Race: Other
Missing Data

New Value
1
2
3
4
5
6
10
14
8
11
12
13
17
18
19
20
21
9
16
23M

For the Research Question 1 multiple linear regression analysis, total QOL was
the dependent variable. The predictors in this model were the recoded primary tumor site,
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race, age groups, and gender variables. The predictors were not significantly related to
total QOL, F (4, 125) = 1.116, p = 0.352. The R-squared (R2) value was 0.034, indicating
that only 3.4% of the variance was explained by this model (the adjusted R2 = 0.004).
Table 18 shows the predictor coefficients for this model, none of which were significant.
Table 18
Predictor Coefficients for Gender, Race, Age Groups, and Primary Tumor Site
B
Age Groups
Gender
Race
Primary Tumor Site

-0.273
-4.523
-0.352
0.982

Standard Standardized
Error
β
3.770
-0.006
2.421
-0.166
1.520
-0.021
1.057
0.083

p-value
0.942
0.064
0.817
0.354

Research Question 2
Research Question 2 and its hypotheses are as follows:
Research Question 2: How does the presence of specific NET biomarkers (NKA,
pancreastatin, serotonin, 5-HIAA, gastrin, and CgA) affect the total QOL score for
NET patients?
H02: The presence of specific NET biomarkers (NKA, pancreastatin, serotonin, 5HIAA, gastrin, and CgA) does not affect the total QOL score for NET patients.
H12: The presence of specific NET biomarkers (NKA, pancreastatin, serotonin, 5HIAA, gastrin, and CgA) affects the total QOL score for NET patients.
In Research Question 2, a series of one-way ANOVAs and a multiple linear
regression analysis were conducted to determine whether total QOL was affected by the
presence of biomarkers. Post hoc tests (Tukey HSD and Games-Howell) were conducted
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for the ANOVAs where appropriate. Any results with a p-value less than 0.05 were
considered significant.
ANOVA results: Total QOL as the dependent variable. A categorical variable
was created for Research Question 2, Presence of Abnormal Biomarkers. For the first
one-way ANOVA, the presence of abnormal biomarker measurements was treated as an
independent variable and total QOL was the dependent variable. This result was
significant, suggesting that the presence of abnormal biomarkers may have a relationship
with total QOL, as shown in Table 19. The η2 value indicated that the presence of
abnormal biomarkers accounted for 15.0% of the variance of total QOL score, which is
moderately strong.
Table 19
One-Way ANOVA Results for Comparison of Total QOL and Presence of Abnormal
Biomarkers

Between Groups
Within Groups
Total

Sum of Squares

Df

Mean Square

F

p-value

η2

48104.53
272147.32
1198996.91

7
109
117

6872.08
2496.76

2.752

0.011*

0.150

*

p < 0.05
Since this analysis did not pass the Levene’s Test of Equality of Error Variances

(test for homogeneity of variances), the Games-Howell post hoc test was used instead of
the Tukey HSD post hoc test. According to the results of the Games-Howell post hoc,
there were significant differences between patients with an abnormal gastrin
measurement only and the following groups: no abnormal biomarker measurement (p =
0.003); an abnormal serotonin measurement only (p = 0.032); an abnormal CgA
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measurement only (p = 0.003); 2 abnormal biomarker measurements (p = 0.000); and 3
or more abnormal measurements (p = 0.000). Ultimately, the result of this ANOVA is
supportive of the alternative hypothesis that the presence of specific NET biomarkers
affected the total QOL score for NET patients.
Toward Research Question 2, I also examined each of the six [Biomarker]
Normal variables as an independent variable with total QOL as the dependent variable
using a one-way ANOVA to determine whether any individual biomarkers affected total
QOL. In the one-way ANOVA for Pancreastatin Normal, the results were not
significant, as shown below in Table 20 (η2 value indicated that this variable only
accounted for 0.7% of the variance of total QOL score). The result of the one-way
ANOVA for NKA Normal was also not significant, as seen in Table 21 (η2 value
indicated that this variable only accounted for 0.1% of the variance of total QOL score).
Table 20
One-Way ANOVA Results for Comparison of Total QOL and the Pancreastatin Normal
Variable

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

1580.72
241223.98
914893.91

1
85
87

1580.72
2837.93

0.557

0.458

0.007

Table 21
One-Way ANOVA Results for Comparison of Total QOL and the NKA Normal Variable

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

88.60
157989.33
567794.00

1
54
56

88.60
2925.73

0.030

0.863

0.001

78
The result of the one-way ANOVA for 5-HIAA Normal was not significant as
well (Table 22; η2 value indicated that this variable only accounted for 0.2% of the
variance of total QOL score). The result of the one-way ANOVA for CGA Normal was
also not significant, as shown in Table 23 (η2 value indicated that this variable only
accounted for 0.4% of the variance of total QOL score). The one-way ANOVA result for
Gastrin Normal did not reach a level of significance (Table 24; η2 value indicated that
this variable only accounted for 0.2% of the variance of total QOL score).
Table 22
One-Way ANOVA Results for Comparison of Total QOL and the 5-HIAA Normal
Variable

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

602.86
247606.19
942594.29

1
85
87

602.86
2913.01

0.207

0.650

0.002

Table 23
One-Way ANOVA Results for Comparison of Total QOL and the CGA Normal Variable

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

1088.91
259459.55
1000976.91

1
97
99

1088.91
2674.84

0.407

0.525

0.004

Table 24
One-Way ANOVA Results for Comparison of Total QOL and the Gastrin Normal
Variable

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

198.03
92296.45
368535.69

1
30
32

198.03
3076.55

0.064

0.801

0.002
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In the one-way ANOVA for Serotonin Normal, the results were significant and
can be seen in Table 25 (η2 value indicated that this variable only accounted for 11.7% of
the variance of total QOL score). Since there were only two levels in the independent
variable, a post hoc test was not necessary. This was the only significant finding in the
one-way ANOVA analyses for the series of [Biomarker] Normal variables.
Table 25
One-Way ANOVA Results for Comparison of Total QOL and Presence of Abnormal
Biomarkers

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

26379.73
198644.11
887065.75

1
81
83

26379.73
2452.40

10.757

0.002*

0.117

*

p < 0.05
Additional ANOVA results: QOL-NET domains as dependent variables.

Additional statistical tests related to Research Question 2 emerged during the analyses of
these data. Specifically, these tests were intended to determine whether any of the
individual domains of the QOL-NET (depression, flushing, respiratory, gastrointestinal,
cardiovascular, physical functioning, and attitude) were affected by the presence of
abnormal biomarker measurements. For each one-way ANOVA, one of the seven
domains was treated as the dependent variable, and the presence of abnormal biomarker
measurements was maintained as the independent variable. Post hoc tests (Tukey HSD
and Games-Howell) were conducted to ascertain whether there were any significant
differences. Any results with a p-value less than 0.05 were considered significant.
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With the exception of the one-way ANOVAs for the gastrointestinal and physical
functioning domains, none of the other results were significant. The result of the one-way
ANOVA with the gastrointestinal domain as the dependent variable and presence of
abnormal biomarker measurements as the independent variable was significant—this
result is shown in Table 26 (η2 value indicated that this variable accounted for 16.8% of
the variance of the domain score).
Table 26
One-Way ANOVA Results for Comparison of the Gastrointestinal Domain and Presence
of Abnormal Biomarkers

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

1144.36
5676.53
17504.00

7
109
117

163.48
52.08

3.139

0.005*

0.168

*

p < 0.05
Since this analysis did not pass the Levene’s Test of Equality of Error Variances

(test for homogeneity of variances), the Games-Howell post hoc test was used instead of
the Tukey HSD post hoc test. According to the results of the Games-Howell post hoc,
there were significant differences between patients with an abnormal CgA measurement
only and patients with 2 abnormal biomarker measurements (p = 0.006).
The result of the one-way ANOVA with the physical functioning domain as the
dependent variable and presence of abnormal biomarker measurements as the
independent variable was also significant (shown in Table 27; η2 value indicated that this
variable accounted for 13.0% of the variance of the domain score).

81
Table 27
One-Way ANOVA Results for Comparison of the Physical Functioning Domain and
Presence of Abnormal Biomarkers

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

p-value

η2

11070.98
74335.58
310959.63

7
109
117

1581.57
681.98

2.319

0.030*

0.130

*

p < 0.05
Since this analysis also did not pass the Levene’s Test of Equality of Error

Variances (test for homogeneity of variances), the Games-Howell post hoc test was used
instead of the Tukey HSD post hoc test. According to the results of the Games-Howell
post hoc, there were significant differences between patients with an abnormal gastrin
measurement and the following groups: patients with no abnormal biomarker
measurement (p = 0.005); patients with an abnormal serotonin measurement only (p =
0.010); patients with an abnormal 5-HIAA measurement only (p = 0.042); patients with
an abnormal CgA measurement only (p = 0.021); patients with 2 abnormal biomarker
measurements (p = 0.000); and patients with 3 or more abnormal measurements (p =
0.002).
Multiple linear regression analysis. For this research question, a multiple linear
regression analysis was conducted to determine whether multiple independent variables
(age, gender, race, and presence of abnormal biomarker measurements) affected total
QOL. As noted earlier in the chapter, the independent variables age, gender, and race
were string variables and had to be recoded to run the multiple linear regression analysis
in SPSS. To recode these variables, the “Automatic Recode” feature was applied to the
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appropriate string variables in SPSS.
The predictors were not significantly related to total QOL, F (4, 111) = 1.514, p =
0.203. The R2 value was 0.052, indicating that only 5.2% of the variance was explained
by this model (the adjusted R2 = 0.018). Table 28 shows the predictor coefficients for this
model.
Table 28
Predictor Coefficients for Gender, Race, Age Groups, and Presence of Abnormal
Biomarker Measurements
B
Age Groups
Gender
Race
Abnormal Biomarker
Presence

-3.921
-4.891
0.489
1.371

Standard Standardized
Error
β
3.946
-0.093
2.498
-0.185
1.437
0.032
1.605
0.081

p-value
0.323
0.053
0.734
0.395

Gender almost reached a level of significance as a predictor (p=0.053), which led
to another linear regression model with gender and presence of abnormal biomarker
measurements as predictors for total QOL. The result for this second regression analysis
was not significant, F (2, 114) = 2.345, p = 0.100. The R2 value was 0.040, indicating that
only 4.0% of the variance was explained by this model (the adjusted R2 = 0.023). Table
29 shows the predictor coefficients for this model.
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Table 29
Predictor Coefficients for Gender and Presence of Abnormal Biomarker Measurements
Unstandardized Coefficients

Constant
Gender
Biomarker
Presence

B
147.920
-4.576
1.282

Standard Error
38.179
2.445
1.570

Standardized
Coefficient
Beta
t-statistic
3.874
-0.173
-1.871
0.076
0.817

Significance
0.000
0.064
0.416

Summary
None of the results from the one-way ANOVAs for Research Question 1 were
significant; thus, they supported the null hypothesis that there is no relationship between
total QOL and primary tumor site. Results from the analyses for Research Question 2
showed that the presence of abnormal biomarker measurements may affect total QOL.
Additionally, it appeared that abnormal serotonin measurements may impact total QOL.
The gastrointestinal and physical functioning domains also appear to be affected by the
presence of abnormal biomarker measurements. An interpretation of the findings from
this study is included in Chapter 5 along with study limitations, recommendations, and
implications for this research.

84
Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
This study was conducted to examine the relationship between NET patients’ total
QOL score and their primary tumor sites in addition to assessing the relationship between
total QOL and novel biomarkers of the disease. For the purpose of this quantitative study,
secondary data from a NET patient database from Eastern Virginia Medical School were
evaluated. Although the results indicated that there was no relationship between primary
tumor site and NET patients’ total QOL score, it does appear that the presence of
abnormal biomarker measurements affected total QOL score. These findings are
discussed in this chapter along with the study’s limitations, recommendations, and
implications.
Interpretation of the Findings
Over half of the patients (65%) in the QOL-NET database responded that they
had NET-related symptoms. This population’s total QOL scores ranged from 5.00 to
230.00, with a mean total QOL score of 90.16 (SD ± 53.43). While 59% of the dataset
population was female, there were no significant differences between the total QOL
scores of female and male patients (F (1,32) = 3.129, p = 0.079). As reported in Chapter
4, age, race, and gender did not affect total QOL. Almost a quarter (23.7%) of the
patients in this dataset had unknown primary tumor sites, which is not unexpected for
NETs.
Research Question 1 inquired about the relationship between the primary tumor
site and NET patients’ total QOL score. Results from the analyses supported the null

85
hypothesis—there was no relationship between primary tumor site and the total QOL
score, even when the primary tumor sites were condensed into their larger organ groups
when possible for analytical purposes (F (8, 125) = 0.834, p = 0.575). It is possible that
the wide range of primary tumor sites and limited number of patients in each group
affected the analysis. Furthermore, primary tumor sites did not have a relationship with
any of the seven domains in the QOL-NET (depression, flushing, respiratory,
gastrointestinal, cardiovascular, physical functioning, and attitude). As part of this
research question, a multiple linear regression analysis was conducted to ascertain
whether multiple independent variables affected total QOL, but the result was not
significant.
In the analyses for Research Question 2, there were significant results that
supported the alternative hypothesis: the presence of specific NET biomarkers affected
the total QOL score for NET patients in this population. These results also contributed to
the body of knowledge about how biomarkers and NETs affect patients’ QOL, and they
warrant further study. In the analysis with the independent categorical variable created
for Research Question 2, Presence of Abnormal Biomarkers, the results of the one-way
ANOVA showed that the presence of abnormal biomarker measures affected total QOL
(p = 0.011) for these patients. Specifically, there appeared to be significant differences
between patients who only had abnormal gastrin measurements and five other categories:
no abnormal biomarker measurement (p = 0.003); an abnormal serotonin measurement
only (p = 0.032); an abnormal CgA measurement only (p = 0.003); 2 abnormal biomarker
measurements (p = 0.000); and 3 or more abnormal measurements (p = 0.000). This

86
finding is noteworthy because there is less information about gastrin as a biomarker for
NETs; consequently, it is known that it can be a biomarker for a variety of NETs,
including those in the bronchus, pancreas, stomach, and duodenum (Modlin et al., 2008).
CgA and serotonin are widely studied NETs biomarkers, and they have been associated
with QOL previously (Ardill & Erikkson, 2003; Eriksson et al., 2000; Korse et al., 2009;
Modlin et al., 2008; A. Vinik et al., 2009). CgA was associated with a common NET
patients’ symptom (diarrhea) in an earlier study (Larsson et al., 2001). In another study,
CgA correlated significantly with overall QOL and physical functioning (Korse et al.,
2009). Serotonin correlated significantly with total QOL from the two NET-specific QOL
instruments and three domains from the QOL-NET (physical functioning, depression, and
gastrointestinal) previously as well (Vinik et al., 2014).
The presence of abnormal biomarker measurements significantly affected the
gastrointestinal domain (p = 0.005) and physical functioning domain (p = 0.030).
According to the post hoc test for the gastrointestinal domain, there were significant
differences between patients with an abnormal CgA measurement only and patients with
2 abnormal biomarker measurements (p = 0.006). This is interesting because it is known
that CgA is secreted in gastrointestinal NETs and other tumor subtypes (Prestifilippo et
al., 2012). It has also been referred to as an important biomarker for diagnosing and
managing gastroenteropancreatic NETs (Lawrence, Gustafsson, & Kidd, et al., 2011). For
the analysis with the physical functioning domain, the post hoc test indicated that there
were significant differences between patients with an abnormal gastrin measurement and
the following groups: patients with no abnormal biomarker measurement (p = 0.005);
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patients with an abnormal serotonin measurement only (p = 0.010); patients with an
abnormal 5-HIAA measurement only (p = 0.042); patients with an abnormal CgA
measurement only (p = 0.021); patients with 2 abnormal biomarker measurements (p =
0.000); and patients with 3 or more abnormal measurements (p = 0.002). Since physical
functioning contributes the most to total QOL in the QOL-NET, it is not surprising that
the post hoc results were similar to those in an earlier study (E. Vinik et al., 2009).
In the analyses of whether the independent [Biomarker] Normal variables
affected the dependent total QOL variable, only the result for Serotonin Normal was
significant (p = 0.002). It appears that the serotonin biomarker affected QOL for NET
patients in this study population. This finding supported previous research that found a
significant correlation between serotonin and three of the QOL-NET domains (physical
functioning, gastrointestinal, and depression) as well as a significant correlation between
serotonin and total QOL (Vinik et al., 2011; Vinik et al., 2014).
With regards to this study’s theoretical framework, the explanatory model of
health promotion and quality of life in chronic disabling conditions, the total QOL scores
alone showed that QOL is impacted by NETs (Stuifbergen et al., 2000). The findings
from Research Question 2 aligned with the theoretical framework—there were different,
independent factors that affected QOL either directly or indirectly (Stuifbergen et al.,
2000). QOL is a multidimensional construct, and the presence of certain NET biomarkers
is likely one of many independent factors that affected total QOL for these NET patients.
Knowing this can help answer the how and why aspects of QOL for these individuals
living with this disease.
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Limitations of the Study
The results of this study are limited to adult patients with NETs ranging from 18
to 85 years of age. It did not appear that age was a limitation in the study, but most
patients were between 40-69 years of age (mean age 57.77 ± 13.64 years). It has been
reported elsewhere that race is a risk factor for NETs, but this patient population was
predominantly white (90%), so I was unable to determine if race was a factor that
affected their total QOL scores (ACS, 2013). Race was not a significant predictor in any
of the multiple linear regression analyses.
There were data available for 134 patients in this dataset, which may have been a
limiting factor. It is possible that more significant results would have been found in a
larger study population. Within the dataset, there were 41 patients who had skipped at
least one question in the QOL-NET. Skipped questions affected total QOL scores as well
as domain scores and could have introduced self-report bias to the results. Although the
Norfolk QOL-NET’s reliability and validity helped avoid instrumentation limitations,
there were instances where an analysis did not pass a test for homogeneity of variances, a
statistical assumption for an ANOVA. (Within the primary tumor site and presence of
abnormal biomarker measurements, there were unequal sample sizes.) To offset this
issue, the Games-Howell post hoc test was conducted because it is meant for unequal
sample sizes and variances.
Information about how the patients in the clinic were different from other patients
was not available, which could be considered an additional limitation. Related to this
limitation, I did not have information about whether or not the patients were referred
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there, and it was unknown how the patients who agreed to participate were different from
those who did not.
Recommendations
It may be difficult to distinguish statistical differences in total QOL scores among
NET patients with different primary tumor sites because this disease has such an impact
on their QOL. It is also possible that a larger study population is needed with more
patients in each primary tumor site group to detect a significant difference. As Lawrence,
Gustafsson, Chan, et al.’s (2011) observed, “There is a distinct epidemiologic profile for
each primary site” (p. 16). It would be worthwhile to conduct similar analyses in a larger
patient population. It could also be valuable to evaluate the QOL scores of this NET
patient population against the QOL scores of a comparable healthy population, as other
studies have demonstrated that NET patients have worse QOL scores than the general
population (Fröjd et al., 2007; Haugland et al., 2013; Larsson et al., 2001; E. Vinik et al.,
2009; Vinik et al., 2011; Vinik et al., 2014; Yadegarfar et al., 2013). Based on findings
that NET biomarkers affected total QOL and measurable QOL domains (i.e., the physical
functioning and gastrointestinal domains of the QOL-NET), further studies about
domain-specific aspects of QOL and NET-specific biomarkers (i.e., gastrin, serotonin, or
CgA) are warranted. Additionally, in future studies (or even a clinical setting), physicians
may want to monitor patient-reported outcomes closely for NET patients who have 2 or
more abnormal biomarker measurements, as it is possible that those biomarkers are
responsible for disease-related symptoms that can challenge patients’ QOL (Haugland et
al., 2013; Kulke et al., 2011; Modlin et al., 2008; Ӧberg & Castellano, 2011).
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Implications
It is clear from this study that NETs affected patients’ QOL, regardless of the
primary tumor site. Results from Research Question 2 contributed new data to the small
yet growing body of knowledge about the relationship between NET biomarkers and
patients’ QOL. Patients, caretakers, and physicians can use that information to develop
approaches to maintaining and improving patients’ QOL throughout their illness. Doing
so would be a positive social change for this patient population and their
caretakers/family members. Additionally, this study can be used to support the need for
further research into the relationship of NET biomarkers and NET patients’ QOL.
Supporting additional research and work that can ultimately help NET patients has the
potential to make a positive social change on a number of communities, from researchers
to patients.
The results also reinforced previous findings about the association between the
serotonin biomarker and total QOL in addition to providing insight into other biomarkers
like gastrin (Vinik et al., 2011; Vinik et al., 2014). This information could be used by
physicians to help NET patients who have abnormal serotonin measurements improve
their well-being. This study also showed that abnormal biomarker measurements affected
the gastrointestinal and physical functioning QOL domains. Through further research,
physicians, patients, and caretakers can gain a better understanding of which aspects of
QOL they can focus on to reduce the effects of specific biomarkers, which could make a
positive impact on NET patients’ lives. Contributing to the improvement of NET
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patients’ well-being through knowledge was a goal of this study, and it is believed that
positive social change can happen based on these results.
Conclusion
NETs are a rare, complicated collection of neoplasms that are difficult to diagnose
and treat. Furthermore, NETs are known to affect patients’ QOL and the measurable
domains that comprise this patient-reported outcome. The results from this study
contribute to NET research by filling gaps in knowledge about QOL and NETs. Although
the research results did not demonstrate that there is a relationship between primary
tumor sites and total QOL, the results do demonstrate that there is a relationship between
the presence of abnormal biomarker measurements and total QOL. Specifically, the
results further support the relationship between serotonin and NET patients’ total QOL in
addition to demonstrating that specific NETs biomarkers may directly affect the
gastrointestinal and physical functioning QOL domains within the Norfolk QOL-NET.
Based on these findings, further research that facilitates a better understanding of NET
biomarkers and their relationship to all aspects of patient QOL is warranted. Ultimately,
the results from this study supported the literature about NET biomarkers’ unique effects
on patients’ QOL, and they contributed to the information about the way NETs can
impact individuals with the disease.
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